nach oben

Erschienen in:

Open Access 01.12.2022 | Review

Biomarkers for sepsis: more than just fever and leukocytosis—a narrative review

verfasst von: Tatiana Barichello, Jaqueline S. Generoso, Mervyn Singer, Felipe Dal-Pizzol

Erschienen in: Critical Care | Ausgabe 1/2022

Abstract

A biomarker describes a measurable indicator of a patient's clinical condition that can be measured accurately and reproducibly. Biomarkers offer utility for diagnosis, prognosis, early disease recognition, risk stratification, appropriate treatment (theranostics), and trial enrichment for patients with sepsis or suspected sepsis. In this narrative review, we aim to answer the question, "Do biomarkers in patients with sepsis or septic shock predict mortality, multiple organ dysfunction syndrome (MODS), or organ dysfunction?" We also discuss the role of pro- and anti-inflammatory biomarkers and biomarkers associated with intestinal permeability, endothelial injury, organ dysfunction, blood–brain barrier (BBB) breakdown, brain injury, and short and long-term mortality. For sepsis, a range of biomarkers is identified, including fluid phase pattern recognition molecules (PRMs), complement system, cytokines, chemokines, damage-associated molecular patterns (DAMPs), non-coding RNAs, miRNAs, cell membrane receptors, cell proteins, metabolites, and soluble receptors. We also provide an overview of immune response biomarkers that can help identify or differentiate between systemic inflammatory response syndrome (SIRS), sepsis, septic shock, and sepsis-associated encephalopathy. However, significant work is needed to identify the optimal combinations of biomarkers that can augment diagnosis, treatment, and good patient outcomes.

A comment to this article is available online at https://doi.org/10.1186/s13054-022-03953-x.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

A biomarker describes a measurable indicator of biological status in normal and pathogenic processes. It may be helpful as a theranostic for identifying suitable patients for therapeutic intervention and titrating the degree and/or duration of intervention. A biomarker should be accurate and reproducible. In the ideal scenario, the biomarker (or combination of biomarkers) should offer both high specificity and sensitivity for diagnosing a condition, but either alone may be adequate as a 'rule-in' or 'rule-out' test.

Sepsis represents a dysregulated immune response to infection that leads to organ dysfunction [1]. Host response biomarkers play a critical role in diagnosis, early recognition of organ dysfunction, risk stratification, prognostication, and patient management, including antibiotic stewardship. Biomarkers may also be helpful for trial enrichment to identify suitable patients and/or risk categorization for an intervention. A wide range of biomarkers, measured by a host of different technologies, are being investigated to discriminate a systemic inflammatory response syndrome (SIRS) rapidly, which is an excessive defensive body's response to a harmful stressor (for example, infection, trauma, surgery, acute inflammation, ischemia or reperfusion, or cancer) [2] or early identification of infection-triggered organ dysfunction (sepsis). Also, the quick sepsis related organ failure assessment (qSOFA) is intended to raise suspicion of sepsis and encourage additional action; although, qSOFA is not a substitute for SIRS [3]. These biomarkers include measurement of acute-phase proteins, cytokines, chemokines, damage-associated molecular patterns (DAMPs), endothelial cell markers, leukocyte surface markers, non-coding RNAs, miRNA, and soluble receptors, as well as metabolites and alterations in gene expression (transcriptomics). Biomarkers may help stratify septic patients into biological phenotypes, for example, hyperinflammatory versus immunosuppressive. Biomarkers can also be used to identify gut permeability, blood–brain barrier (BBB) permeability, probability of hospital readmission, and longer-term outcomes [4, 5].

The causative pathogen replicates and releases its constituents such as endo- and exotoxins, and DNA. These constituents are designated pathogen-associated molecular patterns (PAMPs) [6, 7]. PAMPs are recognized by both pattern-recognition receptors (PRRs) and non-PRRs, which are essential components of the immune system [8, 9]. PRRs include several families, including Toll-like receptors (TLRs), nucleotide-binding oligomerization domain-like receptors (NOD)-like receptors (NLRs), a retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), C-type lectin receptors (CLRs), and intracellular DNA-sensing molecules. Non-PRRs include receptors for advanced glycation end products (RAGE), triggering receptors expressed on myeloid cells (TREM), and G-protein-coupled receptors (GPCRs) [10]. The sensing of PAMPs by immune cell receptors triggers a cascade of signaling pathways that activate multiple transcription factors to promote the production and release of pro- and anti-inflammatory mediators such as acute-phase proteins, cytokines, chemokines, as well as antimicrobial peptides, which are needed to eliminate the invading pathogen [11].

The host immune response and pathogen virulence factors will both trigger cell injury and/or induce cell stress. These results in the release of endogenous molecules (DAMPs), exacerbating the inflammatory response. DAMPs are recognized by the same immune receptors that recognize PAMPs [12, 13]. Many DAMPs have been identified, with some currently used as inflammatory biomarkers. Examples include proteins and cellular molecules related to nucleic acids, such as heat shock proteins (HSPs), the high mobility group box 1 (HMGB-1), and members of the S100 family [12, 14, 15]. The immune response may induce vascular endothelial damage disrupting tight junctions (T.J.), increasing gut permeability, and potentially facilitating translocation of pathogens and/or their PAMPs from the gut to the bloodstream and lymphatics, thereby amplifying the systemic inflammatory response [16]. In addition, an increase of BBB permeability allows circulating immune cells to enter the brain, triggering or exacerbating glial cell activation [17]. These events could trigger an intense and excessive host response activating coagulation and fibrinolytic systems, activating or suppressing hormonal, bioenergetic, and metabolic pathways, and inducing macro- and microcirculatory changes with a net result of multiple organ dysfunction. In the past few decades, researchers have studied each inflammatory response stage during SIRS, sepsis, and septic shock, metabolites associated with inflammatory cascades, and cellular components that could be used as biomarkers. These biomarkers could help identify endothelial damage, intestinal permeability, organ failure, BBB breakdown and predict rehospitalization, short- and long-term mortality, and cognitive consequences in survivors [18].

For this narrative review, we addressed the question, "Do biomarkers in patients with sepsis or septic shock predict mortality, MODS, or organ dysfunction?" Studies were identified by searching PubMed/MEDLINE (National Library of Medicine) databases for peer-reviewed journal articles published until October 2021. The abovementioned databases were searched with the following combinations of keywords: ("inflammatory response syndrome" OR "SIRS" OR "sepsis" OR "septic shock" OR "sepsis-associated encephalopathy" OR "SAE") AND ("markers" OR "biomarkers" OR "biological markers" OR "biological measures" OR "molecular predictor"). We omitted review articles, in vitro studies, and animal studies.

The humoral innate immune response, cytokines, and chemokines

The humoral innate immune response consists of multiple components, including fluid phase pattern recognition molecules (PRMs) and the complement system. PRMs include C-reactive protein (CRP), serum amyloid P component (SAP), and pentraxin 3 (PTX-3) [19]. The rise in CRP level is primarily induced by interleukin (IL)-6 and IL-1β acting on the gene responsible for CRP transcription during the acute phase of an inflammatory process. CRP is a pentameric acute-phase reactant protein whose conformation facilitates the ability to trigger complement activation and activate platelets, monocytes, and endothelial cells [20]. Furthermore, CRP is one of the most widely used and investigated biomarkers [21]. A prospective multicenter cohort study followed 483 adult patients who survived hospitalization for sepsis for up to one year. IL-6, high-sensitivity C reactive protein (hs-CRP), soluble programmed death-ligand 1 (sPD-L1), E-selectin, and intercellular adhesion molecule 1 (ICAM-1) were evaluated at five-time points during and after hospitalization. A comparison was made between a phenotype with hyperinflammation (high levels of IL-6 and hs-CRP) and a phenotype of immunosuppression (high sPD-L1 levels). Compared with a normal phenotype, both hyperinflammation and immunosuppression phenotypes had higher 6-month hospital readmission rates and 1-year mortality rates, both all-cause and attributable to cardiovascular or cancer [22].

Pentraxin (PTX-3) is secreted by macrophages, dendritic cells, macrophages, fibroblasts, mesangial cells, and glial cells under pathogen or inflammatory stimuli [19]. Plasma PTX-3 was assessed on days 1, 2, and 7 in 958 patients with sepsis or septic shock included in the Albumin Italian Outcome Sepsis (ALBIOS) study. The researchers assessed a possible association between PTX-3 levels and clinical severity, organ dysfunction, treatment, and mortality within 90 days. PTX-3 levels were elevated at the onset of sepsis and increased with illness severity and the number of organ dysfunctions. PTX-3 levels decreased between days 1 to 7, but this was less prominent in patients with septic shock [23]. In a prospective observational analysis, PTX-3, IL-6, procalcitonin (PCT), and lactate combined showed excellent performance in predicting 28-day all-cause mortality among patients diagnosed with sepsis or septic shock and superior to the Sequential Organ Failure Assessment (SOFA) score [24].

In a prospective pilot study of markers of complement activation in sepsis, higher C4d (3.5-fold), factor Bb (6.1-fold), C3 (0.8-fold), C3a (11.6-fold), and C5a (1.8-fold) levels were seen compared with healthy volunteer controls [25]. In another study of 49 sepsis patients, 34 developed disseminated intravascular coagulation (DIC), and eight died. Patients with DIC had lower C3 levels and higher SC5b-9 levels. On stratifying by SC5b-9 quartile (ng/mL: low: < 260, moderate: 260–342, high: 343–501, highest: > 501), coagulation parameters were most deranged in the highest quartile with prolonged thrombocytopenia and higher mortality (33%) [26].

The activation of PRRs culminates in the stimulation of transcription factors resulting in the expression and secretion of proinflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), IL-1-β, IL-6, and interferons (IFNs). These inflammatory mediators are required for host defense against pathogens and activation of the adaptive immune response. A retrospective study evaluated a broad panel of cytokines and found IL-1β, IL-6, IL-8, MCP-1, IL-10, and plasminogen activator inhibitor 1 (PAI-1) levels were increased in the acute phase of sepsis in both critically and non-critically ill patients. In addition, levels of IL-10 (days 1, 2, and 4), IL-6 and PAI-1 (days 2 and 4), and IL-8 (day 4) increased in critically ill patients compared to non-critically ill [27]. In summary, hs-CRP, IL-6, and PAI-1 circulatory levels may have utility in stratifying a hyperinflammatory patient phenotype.

DAMPs

DAMPs are endogenous danger molecules released from damaged or stressed cells. These molecules activate the innate immune system through interaction with PRRs. DAMPs contribute to the host defense but can also promote pathological inflammatory responses. Calprotectin, a protein found in the cytosol of neutrophils and macrophages, is released under cell stress or damage. In a mixed population study, plasma calprotectin levels were higher in sepsis than in trauma patients and other medical conditions. Calprotectin levels were higher in patients who did not survive for 30 days. Plasma PCT did not differ between the groups or as a prognosticator of the outcome. Receiver operating characteristic (ROC) analysis, used as a sepsis biomarker, had a higher area under the curve (AUC) value for calprotectin (AUC: 0.79) compared to PCT (AUC: 0.49) [28].

A prospective study evaluated IL-6, HMGB-1, and neutrophil gelatinase-associated lipocalin (NGAL) in 14 septic patients and 16 patients without sepsis admitted to the ICU. In patients with sepsis, IL-6 decreased levels were associated with ICU survival; NGAL levels rose in non-survivors, while HMGB-1 levels were unchanged in both survivors and non-survivors regardless of complications [29].

Endothelial cells and BBB markers

The first step in endothelial and BBB injury is the breakdown and destruction of proteins followed by release into the bloodstream. These proteins or peptides can be evaluated as a marker of endothelial cells and BBB integrity [30]. Plasma levels of occludin (OCLN), claudin-5 (CLDN-5), zonula-occludens 1 (ZO-1), PCT, and lactate were assessed in 51 septic patients. OCLN and ZO-1 were elevated with disease severity and positively correlated with the Acute Physiology and Chronic Health Evaluation II (APACHE-II) and SOFA scores and lactate levels. The predictive value for in-hospital mortality of ZO-1 was comparable to that of lactate levels, APACHE-II, and SOFA scores but superior to OCLN and PCT [31]. In a case series of brain autopsies from adults who died from sepsis, 38% had no OCLN expression in the endothelium of cerebral microvessels. BBB damage was associated with higher maximum SOFA scores and PCT levels > 10 μg/L. BBB damage in the cerebellum was more common with CRP values > 100 mg/L [32]. Soluble fms-like tyrosine kinase 1 (sFlt-1), soluble E-selectin (sE-selectin), soluble intercellular adhesion molecule 1 (sICAM-1), soluble vascular cell adhesion molecule 1 (sVCAM-1), and PAI-1 were evaluated in another studies. All these evaluated endothelial biomarkers were associated with sepsis severity. sFlt-1 had the strongest association with the SOFA score, while sFlt-1 and PAI-1 had the highest area under the operating receiver characteristic curve for mortality [33].

Syndecan-1 is a structural component of the endothelium. Antithrombin, PAI-1, syndecan-1, VCAM-1, E-selectin, IL-1β, IL-6, IL-8, HMGB-1, and histone-H3 were increased in septic patients compared with healthy controls. Non-survivors had a higher syndecan-1 level compared with survivors. On day one, an association was seen between syndecan-1 levels and APACHE-II, SOFA, DIC scores, hemostatic markers, IL-1β, IL-8, and PAI-1. Day 1 syndecan-1 levels were also significantly higher in patients with DIC and had reliable discriminative power to predict both DIC development and subsequent mortality [34].

The serum biomarker, calcium-binding protein B (S100B), reflects BBB disruption, glial cell injury, and activation. S100B is used to evaluate brain injury severity and predict outcomes from stroke, traumatic brain injury, encephalopathy, and delirium [35]. A prospective cohort study demonstrated that day three values for predicting 180-day mortality were superior to day one (0.731 vs. 0.611) [36]. Patients with sepsis-associated encephalopathy also had elevated levels. In another observational study of 22 patients with septic shock, delirium was present in ten. The odds ratio for the risk of developing delirium with an S100B > 0.15 μg/L was 18.0. Patients with delirium had higher plasma levels of IL-6. S100B and IL-6 levels were positively correlated [37]. S100B, PAI-1, angiopoietin (Ang)-2, ZO-1, and OCLN are the main biomarkers currently used to evaluate the vascular injury and BBB permeability.

Gut permeability markers

Critically ill patients show an increase in gut permeability, which may trigger a systemic inflammatory response syndrome and multiple organ dysfunction syndromes (MODS) [38]. Plasma zonulin levels were higher in sepsis patients compared to a post-surgical control group or healthy volunteers [39]. In another study, serum levels of intestinal fatty acid-binding protein (I-FABP) were higher in patients with sepsis and higher still in those with septic shock. Serum D-lactic acid levels were also elevated with sepsis but did not differentiate severity. Neither I-FABP nor D-lactic acid could prognosticate [40].

Non-coding RNAs and miRNA

A non-coding RNA (ncRNA) is an RNA molecule transcribed from DNA but not translated into proteins. A microRNA is a small non-coding RNA molecule that functions in RNA silencing and post-transcriptional gene expression regulation. ncRNAs and mRNAs are being studied as sepsis biomarkers. For example, long non-coding metastasis-associated lung adenocarcinoma transcript 1 (lnc-MALAT1) and micro RNA (miR)-125a were increased in sepsis patients compared with healthy controls and positively correlated with APACHE-II score, SOFA score, serum creatinine, CRP, TNF-α, IL-1β, IL-6, and IL-8. The lnc-MALAT1/miR-125a axis was also a predictor of increased 28-day mortality risk [41]. In another study lnc-MALAT1 expression was increased in acute respiratory distress syndrome (ARDS) patients compared to non-ARDS patients (AUROC: 0.674). Nonsurvivors compared to survivors (AUROC: 0.651) and positively correlated with APACHE-II and SOFA scores, CRP, PCT, TNF-α, IL-1β, IL-6, and IL-17 [42]. Long non-coding RNA maternally expressed gene 3 (lnc-MEG3), and the lnc-MEG3/miR-21 axis were increased, while miR-21 expression was decreased in sepsis patients compared with healthy controls. lnc-MEG3 (AUROC: 0.887) and the lnc-MEG3/miR-21 ratio (AUROC: 0.934) had high values for predicting elevated sepsis risk, while miR-21 (AUROC: 0.801) gave excellent predictive value for a reduced sepsis risk [43]. A further study showed miR-125a and miR-125b expressions were elevated in sepsis patients compared with healthy controls and were predictive of sepsis risk—miR-125a (AUROC: 0.749) and miR-125b (AUROC: 0.839). No correlation was seen between miR-125a and CRP, TNF-α, IL-6, IL-17, and IL-23 in however, miR-125b was positively associated with these cytokines. miR-125a failed to predict 28-day mortality risk (AUROC: 0.588) in sepsis patients, whereas miR-125b was superior (AUROC: 0.699) [44].

Membrane receptors, cell proteins, and metabolites

Cell surface receptors are receptors incorporated into the plasma membrane of cells and act on cell signaling by receiving or binding to extracellular molecules. After detecting such molecules, the production of metabolites occurs. In one study, the cluster of differentiation (CD)-13, CD14, CD25, CD64, and human leukocyte antigen (HLA-DR) showed acceptable sensitivity and specificity for mortality prediction (CD13 AUROC:0.824; CD64 0.843; and HLA-DR 0.804) while CD14 and CD25 did not predict mortality [45]. nCD64 expression, in a further study, nCD64, PCT, CRP, and SOFA scores were higher in septic patients, with nCD64 having the highest AUC (0.879) for differentiating a positive microbial culture. This was superior to PCT (0.868), SOFA score (0.701), CRP (0.609), and white blood cell (WBC) count. In predicting 28-day mortality, the combination of nCD64 and SOFA score had an AUROC of 0.91 versus 0.882 for the combination of PCT and SOFA [46].

A meta-analysis of 19 studies enrolling 3012 patients evaluated the value of PCT (AUROC 0.84) and presepsin (0.87 AUROC) for diagnosing sepsis. The pooled sensitivities and specificities were 0.80 and 0.75 for PCT and 0.84 and 0.73 for presepsin [47]. In one study, levels of presepsin, PCT, CRP, and WBC were higher in sepsis patients than in a SIRS group with AUROC values of 0.954 (presepsin), 0.874 (PCT), 0.859 (CRP), and 0.723 (WBC). The cut-off of presepsin for discriminating between sepsis and SIRS was 407 pg/ml, with sensitivity and specificity values of 98.6% and 82.6%, respectively [48]. In a study of septic children, TREM-1 levels were higher in septic shock patients [49].

Hormones and peptide precursors

Adrenomedullin (ADM) is synthesized in different tissues, including the adrenal cortex, kidney, lung, blood vessels, and heart. It has biological properties, including vasodilating, inotropic, diuretic, natriuretic, and bronchodilating. In one study, mid-regional pro adrenomedullin (MR-proADM) was an independent predictor of five different organ failures (respiratory, coagulation, cardiovascular, neurological, and renal), compared to lactate which predicted three (coagulation, cardiovascular and neurological), PCT two (cardiovascular and renal) and CRP (none) [50]. MR-proADM most accurately identified patients with a high likelihood of further disease progression compared to other biomarkers and clinical scores [51]. A total of 1089 individuals with either sepsis (142) or septic shock (977) were included in a randomized controlled study. The MR-proADM level within the first 24 h after sepsis diagnosis was associated with 7-day mortality (AUROC 0.72 and p < 0.001) and 90-day mortality (AUROC 0.71 and p < 0.001). Patients with declining PCT levels but persistently high MR-proADM levels on day-1 or day-4 had a substantially higher mortality risk of 19.1 (8.0–45.9) and 43.1 (10.1–184.0), respectively [52]. Adult patients hospitalized to ICU had their bioactive-ADM levels measured in this retrospective observational study. This study comprised a total of 1867 patients, 632 septic patients, and 267 septic shock patients. The median bioactive-ADM was 74 pg/mL in sepsis patients, 107 pg/mL in septic shock, and 29 pg/mL in non-septic patients. The association of elevated bioactive-ADM and mortality in sepsis patients and the ICU population resulted in O.R.s of 1.23 and 1.22, respectively [53]. In addition, the MR-proADM is potentially removal by continuous renal replacement therapy (CRRT) [54].

N-terminal (N.T.)-prohormone BNP (NT-proBNP) is a non-active prohormone produced by the heart and released in response to changes in intracardiac pressure. Higher levels of NT-proBNP at 24 h after sepsis onset were associated with lower short physical performance battery (SPPB) scores at 12 months and lower handgrip strength at 6-month and 12-month follow-up. NT-proBNP levels during the acute phase of sepsis may thus be a valuable indicator of a greater risk of long-term impairment in physical function and muscle strength in sepsis survivors [55]. In another study, NT-proBNP levels on admission were higher in-hospital non-survivors (7908 pg/mL) compared with survivors (3479 pg/mL). AUROC curves of admission and 72-h NT-proBNP levels for hospital mortality were 0.631 and 0.648, respectively [56].

PCT is produced in the thyroid's C cells and converted to calcitonin, with no PCT released into the bloodstream. During inflammatory processes, PCT is produced directly by stimulating bacterial components or induced by various inflammatory mediators such as IL-6 and TNF-α. PCT and presepsin had similar performance in predicting positive sepsis results with AUROC values of 0.75 and 0.73, respectively [57]. Another investigation gave AUROC values of 0.87 for PCT and 0.78 for presepsin in predicting bacteremia [58]. Plasma levels of presepsin and PCT were progressively higher in sepsis and septic shock than in non-septic patients. Presepsin was superior to PCT in diagnosing severe community-acquired pneumonia [59], while PCT was marginally superior in another study of septic patients admitted to intensive care [60]. On the other hand, MR-proADM had a better predictive value for septic shock. This study concluded that PCT, MR-proADM, and presepsin are complementary biomarkers that could have utility in the management of septic patients. In an intention-to-treat study comparing PCT versus no PCT guidance, there was no significant difference in 28-day mortality (25.6% PCT versus 28.2% no PCT, p = 0.34). The use of procalcitonin did not impact investment decisions as measured by the frequency of therapeutic and diagnostic interventions. [61].

High levels of resistin collected on day 1 of ICU admission were associated with an increased likelihood of developing new organ failure, whereas high myeloperoxidase (MPO) levels on day one were associated with an increased risk of developing incident organ failure for clotting and kidney systems [62].

Soluble receptors

Soluble trigger receptor expressed in the myeloid cell-1 (sTREM-1) is a TREM family member. This receptor offers excellent potential as a biomarker for infectious diseases as it can be measured in different biological fluids, including serum, pleural fluid, sputum, and urine [63]. However, a meta-analysis of 2418 patients enrolled in 19 studies showed serum sTREM-1 had only moderate accuracy in diagnosing patients with suspected sepsis [63]. Combining sTREM-1 with clinical variables offered more significant mortality discrimination compared to clinical variables alone [64]. In a multicenter prospective cohort study, soluble tumor necrosis factor receptor type 1 (sTNFR1) levels > 8861 pg/ml predicted 30-day mortality [65].

Patients with sepsis or septic shock displayed higher levels of the soluble form of the urokinase plasminogen activator receptor (suPAR), PCT, and lactate on days 1, 2, 4, and 7 of admission, with lactate and suPAR being the best risk stratifies for suspected infection [66]. Levels of suPAR and PCT levels were higher in sepsis patients than in a SIRS group with AUROC values of 0.89 and 0.82, respectively [67]. Serum sPD-L1 levels were increased in non-survivors compared with survivors with similar prognostic accuracy for 28-day mortality as APACHE-II and SOFA scores [68]. See Tables 1 and 2 for further information, as well as Fig. 1.

Table 1

Different roles of the biomarkers in sepsis

Biomarker	Function	References
Acute-phase proteins
CRP, hsCRP	Response to infection and other inflammatory stimuli	[4, 69, 70]
	Predictive for increased 28-day mortality in patients with sepsis
	Hyperinflammatory phenotype
Complement	Prognosis of disease severity	[25, 71]
Proteins	C5a can be predictive for DIC
PTX-3	Discrimination of sepsis and septic shock	[72, 73]
	Diagnosis of sepsis and septic shock during the first week in the ICU
	Prediction of septic shock
Cytokines and chemokines
IL-10	Hypoinflammatory phenotype	[22, 71]
MCP-1	It differentiates patients with septic shock from patients with sepsis	[73, 74]
	Mortality prognosis at 30 days and six months
TNF-α, IL-1β, IL-6	IL-6 all-cause mortality prognosis at 30 days and six months	[27, 74]
	IL-1β and IL-6 acute phase of sepsis
	It was increased in the hyperinflammatory phenotype
	Organ dysfunction prognosis
DAMPs
Calprotectin	PCT to distinguish between patients with sepsis and patients without sepsis in the ICU	[28]
	Predictive for 30-day mortality
HMGB-1	Worst prognosis and higher 28-day mortality	[75, 76]
Endothelial cells and BBB markers
Syndecan-1	Increase related to sepsis severity	[34]
	Discriminative power for DIC and subsequent mortality
VLA-3 (a3β1)	Indicative of sepsis	[77, 78]
	Discrimination of sepsis and SIRS
Ang-1	It stabilizes the endothelium and inhibits vascular leakage by constitutively activating the Tie-2 receptor	[79]
	Ang-2/Ang-1, Ang-1/Tie-2 ratio has a prognosis for 90-day mortality in sepsis and septic shock in the ICU higher than the PCT and SOFA score
	Independent and effective predictors of SOFA score changes
Ang-2	It can disrupt microvascular integrity by blocking the Tie-2 receptor, which results in vascular leakage	[73, 79]
	Individuals with septic shock had higher levels of Ang-2 than those with sepsis
CLDN-5	The absence of CLDN-5 may indicate damage to endothelial cells during sepsis	[31]
OCLN	Increase related to sepsis severity and positive correlation with SOFA scores	[31, 32]
	Predictive of mortality
	The absence of OCLN in the cerebral microvascular endothelium was related to more severe disease and intense inflammatory response
PAI-1	Sepsis severity prognosis	[33, 34]
	Predictor of mortality
	An increase may indicate DIC
sICAM-1	Sepsis severity prognosis	[33, 79]
	Prognosis of 90-day mortality in patients with sepsis and septic shock in the ICU
S100B	It is associated with delirium in septic shock	[36, 37, 80]
	Prognosis of severe organ dysfunction
	Shortest survival in 180 days
	Diagnosis of sepsis-associated encephalopathy
E-selectin	Sepsis severity prognosis	[33]
	Predicts mortality
	Increase related to SOFA and APACHE-II
sFlt-1	Prognosis of sepsis severity and SOFA score,	[33]
	The prognosis for morbidity and mortality
sVCAM-1	Prognosis of sepsis severity and 28-day mortality	[33, 79, 81]
	Prognosis of 90-day mortality in patients with severe sepsis and septic shock in the ICU
	Risk of septic shock
ZO-1	Prognosis of sepsis severity and correlation with APACHE-II and SOFA scores	[31, 32]
	Predictor of mortality
	Diagnostic capability for MODS
Gut permeability markers
Citrulline	The decrease may indicate early acute bowel dysfunction	[82, 83]
I-FABP	Risk of septic shock	[40]
	Indicates early intestinal damage in patients with sepsis and septic shock
Zonulin	Indicates intestinal permeability during sepsis and SIRS	[39]
D-lactic acid	Indicates early intestinal damage in patients with sepsis and septic shock	[40]
Non-coding RNAs
Lnc-MALAT1	The distinction between septic and non-sepsis patients	[41, 42]
	Positive correlation with APACHE-II
	Sepsis severity prognosis
	High risk of ARDS
	Predictive for high mortality
	The increase can distinguish ARDS from non-ARDS
lnc-MEG3	The increase is predictive of sepsis	[43]
	28-day mortality risk
miRNA
miR-125a, miR-125b	Prognosis of more significant disease severity	[44, 84, 85]
	Distinguishes patients with sepsis from patients without sepsis
	miR-125b: increased risk of mortality in patients with sepsis
	miR-125a: risk of sepsis and increased mortality
Membrane receptors, cell proteins, and metabolites
CD64	Prognosis of disease severity	[46]
	28-day mortality predictor
	Early diagnosis of infection
CD68	Prognosis of disease severity	[86]
	Microglial activation
NFL	Indicates risk and severity of sepsis-associated encephalopathy	[87]
NFH	Indicates risk and severity of sepsis-associated encephalopathy	[87]
NSE	Diagnosis of sepsis-associated encephalopathy	[80, 88]
	30-day mortality risk
	Risk of delirium
	Neuronal injury marker in sepsis
Presepsin	Initial diagnosis and sepsis risk stratification	[48]
	Potential marker to distinguish Gram ( +) and Gram (-) bacterial infection
TREM-1	Sepsis indicator	[89‐91]
	An early distinction between sepsis and SIRS
	Predictive of septic shock
Peptide precursor of the hormone and hormone
MR-proADM	Discrimination of survivors and non-survivors	[92]
	Organ dysfunction marker
PCT	Diagnosis of sepsis	[66, 90]
	Predicts Bacterial Infection
NT-proBNP	In the acute phase of sepsis it indicates a risk of long-term impairment of physical function and muscle strength	[55]
	Predict mortality risk	[52]
Neutrophil, cells, and related biomarkers
Lactate	Predictive of mortality	[93]
	Risk stratification of patients with suspected infection
MPO	Increase in patients with DIC	[94, 95]
	Indicates organ dysfunction
	Mortality predictor at 28 and 90 days
	Risk of septic shock
	NET generation
Resistin	Sepsis indicator	[96, 97]
	Risk of septic shock
	28-day mortality predictor
Soluble receptors
sPD-L1	Prognosis of disease severity	[4, 68]
	28-day mortality predictor
	Indicates immunosuppression
suPAR	Predictive mortality at 7 and 30 days	[66]
	Risk of patients with suspected infection
sTNFR-1	Prognosis of 28-day mortality	[81, 98]
	Risk of septic shock
	Risk of delirium
Lipoproteins
LDL-C	Protective effect against sepsis	[99]
	The decrease can cause a risk of sepsis and admission to the ICU
HDL	Low levels: mortality prognosis and adverse clinical outcomes	[100, 101]
	Predictive for MODS
T-chol	The decrease has a worse prognosis in sepsis	[102]

Ang-1 angiopoietin-1, Ang-2 angiopoietin-2, APACHE-II acute physiology and chronic health evaluation II, ARDS acute respiratory distress syndrome, CD cluster of differentiation, CLDN-5 claudin-5, CRP C reactive protein, DAMPs damage-associated molecular patterns, DIC disseminated intravascular coagulation, HDL high-density lipoprotein, HMGB1 high mobility group box 1, hsCRP high-sensitivity C reactive protein, ICU intensive care unit, I-FABP intestinal fatty acid binding protein, IL interleukin, LDL low-density lipoprotein, lnc-MALAT1 long non-coding metastasis-associated lung adenocarcinoma transcript 1, lnc-MEG3 long non-coding RNA maternally expressed gene 3, MCP-1 monocyte chemoattractant protein-1, miR-125a micro RNA-125a, miR-125b micro RNA-125b, MODS multiple organ dysfunction syndrome, MPO myeloperoxidase, MR-proADM mid-regional pro adrenomedullin, NFL neurofilament light, NFH neurofilament heavy, NSE neuron specific enolase, NT-proBNP N-terminal pro-brain natriuretic peptide, OCLN occludin, OR odds ratio, PAI-1 plasminogen activator inhibitor 1, PCT procalcitonin, PTX-3 pentraxin-3), S100B calcium-binding protein B, sFlt-1 soluble fms-like tyrosine kinase 1, sICAM-1 soluble intercellular adhesion molecule 1, SIRS systemic inflammatory response syndrome, SOFA sequential organ failure assessment, sPD-L1 soluble programmed death ligand 1, sTNFR1 soluble tumor necrosis factor receptor type 1, suPAR soluble form of the urokinase plasminogen activator receptor, sVCAM-1 soluble vascular cell adhesion molecule 1, T-chol total cholesterol, TNF-α tumour necrosis factor alpha, TREM-1 triggering receptor expressed on myeloid cells-1, VLA-3/a3β1 integrin alpha 3 beta 1, ZO-1 zonula-occluden 1

Table 2

Biomarkers for sepsis, septic shock, and sepsis-associated encephalopathy

Biomarker	Sample	Demographic	Specificity (%)	Sensitivity (%)	Cut-off	R²	AUC	Clinical relevance	References
Acute-phase proteins
CRP, hsCRP	Plasma and serum	Sepsis = 483	–	–	15–20 mg/dl	–	–	↑ hsCRP hyperinflammatory phenotype	[22]
		Mean age mean = 60.5	–	–	–	–	–	↑ hsCRP day 1 to 2, 95.8%
		♂ 54.9%	–	–	–	–	–	↑ hsCRP, 23 patients (25.8%) at 3, 26 patients (30.2%) at 6, and 23 patients (25.6%) at 12 months
	Plasma	Sepsis = 43	–	–	–	–	0.51, 0.56, and 0.48	CRP, day 1, 3, and 8 to predict 30-day mortality p = 0.836, p = 0.059, and p = 0.819, respectively	[74]
		Septic shock n = 93
		Age = 26 to 88
	Plasma	Sepsis = 17	61.54%	52.17%	9 mg/dl	–	0.684	↑ hsCRP sepsis versus control group, p = 0.008	[103]
		Control = 19
		Age = 52.18
		♂ 63%
	Serum	Sepsis = 38	100%	88.40%	8.02 mg/l	–	0.98	↑ CRP in septic patients compared to control group, p = 0.001	[104]
		Septic shock = 31 Control = 40
		Age = 37 to 95
		♂ 57.89%
	Serum	Sepsis = 27	75.00%	78.00%	7.4 mg/dl	–	0.825	↑ hsCRP sepsis versus control group, p = 0.001	[105]
		Septic shock = 23	–	–	–	–	0.751	↑ hsCRP septic shock versus sepsis, p = 0.002
		Control = 20	–	–	–	0.686	–	↑ hs-CRP level versus SOFA, p < 0.001
		Age = 85
		♂57.89%
	Blood	Sepsis = 33	90.70%	98.60%	407 pg/ml	-	0.859	↑ CRP in sepsis patients compared in SIRS group, p < 0.05	[48]
		Severe sepsis = 24
		Septic shock = 15
		SIRS = 23
		Normal = 20
		Mean age = 62.1
	Serum	Sepsis = 119	-	-	-	-	-	↑ CRP and SOFA score in the sepsis group compared to the control group, p < 0.05	[46]
		Septic shock = 32						↔ Septic shock group when compared with sepsis group, p = 0.086
		Control = 20	–	–	–	–	–	↔ Diagnosing positive infection culture in patients with sepsis, p = 0.071
			–	–	–	–	0.609
	Serum	Severe sepsis = 34	–	–	–	–	–	↔ CRP did not differentiate septic shock and severe sepsis	[89]
		Septic shock = 53
		Age = 2 mo to 16 years
Complement	Plasma	Sepsis = 20	–	–	–	–	–	↑ Sepsis (C4d 3.5-fold; Factor Bb 6.1-fold; C3 0.8-fold; C3a 11.6-fold; and C5a 1.8-fold) versus control	[25]
Proteins		Control = 10						↑ C5a ↓ SOFA
		Age = 85	–	–	–	0.18	–
		♂57.89%					–
PTX-3	Plasma	Sepsis = 73	–	–	–	0.36	–	↑ PTX-3 versus APACHE-II, and SOFA, p = 0.0001	[72]
		Control = 77	–	–	31.4 ng/ml	–	–	Sepsis versus SIRS, p > 0.05
		Septic Shock = 140	–	–	–	–	–	Sepsis versus septic shock, p = 0.0001
		Age = 26 to 88	–	–	–	–	–	↑Sepsis/septic shock versus control, p ≤ 0.001
		♂57.89%	–	–	–	–	0.82 and 0.73	Sepsis and septic shock discrimination on day 1
	Plasma	Sepsis = 17	–	–	–	–	–	↑ PTX-3 sepsis, septic shock, and post-surgery infection versus control group, p < 0.05	[73]
		Septic shock = 26						↑ PTX-3 sepsis shock versus sepsis, p < 0.0001
		Post-surg. Inf. = 33	–	–	–	–	0.798
		Control = 25
Cytokines and chemokines
IL-10	Plasma	Sepsis = 208 Control = 210	–	–	–	–	− 0.161	↑ miR-126 correlated negatively with IL-10, p = 0.020	[106]
	Plasma	Sepsis = 309	–	–	–	–	− 0.166	↑ lncRNA ITSN1-2 correlated negatively with IL-10, p = 0.003	[107]
		Mean age = 57,3 ± 9,7
		Control = 330
		Mean age = 55,8 ± 9,7
MCP-1	Plasma	Sepsis = 43	–	–	–	–	0.64, 0.51, and 0.51	MCP-1, day 1, 3, and 8 to predict 30-day mortality, p = 0.004, p = 0.948, and p = 0.948, respectively	[74]
		Septic shock n = 93
		Age = 26 to 88
	Plasma	Sepsis = 17	–	–	–	–	–	↑ MCP-1 sepsis, septic shock and post-surgery infection versus control group, p < 0.05	[73]
		Septic shock = 26						↑ MCP-1 sepsis shock versus sepsis, p = 0.0059
		Post-surg. Inf. = 33	–	–	–	–	0.71
		Control = 25
TNF-α, IL-1β, IL-6	Serum	Sepsis = 288	–	–	–	–	–	↑ Sepsis TNF-α, IL-1β, IL-6, and IL-8 compared to the control group, p < 0.001	[70]
		Mean age = 58.2 ± 11.2						↑ TNF-α, IL-1β, IL-6, and IL-8 were negatively correlated with surviving sepsis patients, p < 0 .001
		Control = 290	–	–	–	–	− 0.270,
		Mean age = 56.8 ± 12.1					− 0.310,
							− 0.254, and
							− 0.256
	Plasma	Sepsis = 483	–	–	10² pg/dl	–	–	↑ IL-6, 72 patients (74.2%) at 3 months, 62 (70.5%) at 6 months, and 59 (66.3%) at 12 months	[22]
		Age mean = 60.5
		♂ 54.9%
	Serum	Sepsis = 43	–	–	–	–	0.69, 0.70, and 0.68	↑ IL-6, day 1, 3, and 8 to predict 30-day mortality, p = 0.0001, p = 0.0001, and p = 0.012, respectively	[74]
		Septic shock n = 93
		Age = 26 to 88
	Serum	Sepsis = 39	–	–	12,704—111,372	–	–	↑ IL-6 septic patients with DIC, p = 0.01	[34]
		Control = 15			pg/ml
		Age ≥ 18 years
DAMPs
Calprotectin	Plasma	Sepsis = 77	56%	81%	1.3 mg/l	–	–	↑ Calprotectin, sepsis versus trauma patients, p < 0.001	[28]
Calprotectin	Plasma	Trauma = 32	–	–	–	–	–	↑ Calprotectin at admission was ↑ in non-survivors than in survivors at day 30, p < 0.01	[28]
HMGB-1	Serum	Sepsis = 247	–	–	3.6 ng/ml	–	–	↑ HMGB-1 sepsis versus control, p < 0.001	[75]
			–	–	–	–	0.51 and 0.53	HMGB-1, day 0 and 3, survivor = non-survivor
			–	–	–	–	–	HMGB-1 does not have predictive value for organ failure and outcome
Endothelial cells and BBB markers
Syndecan-1	Serum	Sepsis = 39	–	–	–	–	–	↑ Syndecan-1 in sepsis versus control, p < 0.0001	[34]
		Control = 15	–	–	–	–	–	↑ Syndecan-1 non-survivors on days 1, 2, and 4
		Age	–	–	–	–	0.54 and 0.59	↑ Syndecan-1 versus DIC on day 1 and 2, p = 0.0004 and p = 0.0002, subsequently
		Age ≥ 18 years	–	–	189–1301 ng/ml	–	–	↑ Syndecan-1 in septic patient with DIC, p < 0.01
VLA-3 (a3β1)	Neutrophil	SIRS = 9	–	–	–	–	–	↑ α3β1 (VLA-3, CD49c/CD29) on neutrophils of septic patients, p < 0.05	[77]
		Sepsis = 15
		Control = 7
		Sepsis = 6	–	–	–	–	–	↑ β1 (CD29), on neutrophils of sepsis patients, p < 0.05	[78]
		Control = 5	–	–	–	–	–	↑ β1 (CD29), on neutrophils of sepsis patients, p < 0.05	[78]
Ang-1	Serum	Severe sepsis = 48	–	–	–	–	–	↑ Ang-1 severe sepsis compared with shock septic, p < 0.01	[79]
		Septic shock = 54						↓ Ang-1/Tie-2 in non-survivors, p < 0.001
		Age ≥ 18 years	–	–	3.81–16.1 ng/ml	–	–
	Plasma	SIRS = 943	–	–	–	–	–	↑ Ang-1 was associated with a reduced risk of shock. OR: 0.77	[81]
		Sepsis = 330						↑ Ang-1 was higher in survivor versus non-survivor, p < 0.001
		Shock = 216	–	–	5719 pg/ml	–	–
		Pneumonia = 169
		Others = 152
		Age = 55.1 ± 16.1
		♂ 63.9%
Ang-2	Serum	Severe sepsis = 48	–	–	–	–	–	↑ Ang-2 severe sepsis compared with shock septic, p < 0.02	[79]
		Septic shock = 54						↓ Ang-2/Ang-1 in non-survivors, p < 0.001
		Age ≥ 18 years	–	–	–	–	–
	Plasma	SIRS = 943	–	–	–	–	–	↑ Ang-2 was associated with an increased risk of shock, OR: 1.63	[81]
		Sepsis = 330	–	–	42.063 pg/ml	–	–	↑ Ang-2 non-survivor, p < 0.001
		Shock = 216
		Pneumonia = 169
		Others = 152
		Age = 55.1 ± 16.1
		♂ 63.9%
CLDN-5	Serum	Sepsis = 11	–	–	–	–	–	↑ CLDN-5 was not associated with MODS and the non-MODS group	[31]
		Severe sepsis = 18	–	–	–	–	0.157 and 0.087	↑ CLDN-5 was not correlated with SOFA or APACHE score, p = 0.270, p = 0.542
		Septic shock = 22	–	–	–	–	–	Did not predict mortality
	Serum	Sepsis = 11	–	–	–	–	–	CLDN-5 was absent from the endothelium	[32]
		Severe sepsis = 18
		Septic shock = 22
OCLN	Serum	Sepsis = 11	–	–	–	–	–	↑ OCLN in severe sepsis and septic shock than in sepsis, p < 0.05	[31]
		Severe sepsis = 18	–	–	–	–	–	↑ OCLN in non-survivors compared with survivors, p < 0.01
		Septic shock = 22	–	–	–	–	0.337	↑ OCLN positively correlated with SOFA, p < 0.016
			–	–	–	–	0.224	↔ OCLN levels were not correlated with the APACHE-II, p < 0.085
	Brain tissue autopsies	Sepsis = 47	–	–	–	–	–	↓ OCLN, cerebellar endothelium damage, ↑ CRP ≥ 100 mg/l	[32]
			–	–	–	–	–	38% of patients (18/47) had no expression of OCLN in the BMVECs
			–	–	–	–	–	34% of patients (16/47) had MOFs
			–	–	–	–	–	74.5% of patients (35/47) had septic shock
			–	–	–	–	–	The deceased with BBB damage had SOFA scores six versus 14, p = 0.04
PAI-1	Plasma	Sepsis = 63	–	–	–	–	0.85	↑ PAI-1 to predict mortality, p < 0.05	[33]
		Severe sepsis = 61	–	–	–	0.45	–	↑ PAI-1 correlated with the SOFA score at 24 h, p < 0.0001
		Septic shock = 42	–	–	–	0.58	–	↑ PAI-1 correlation with APACHE-II score, p < 0.0001
		Age = 60 ± 17	–	–	–	–	–	↑ Severe sepsis ↑ sFlt-1, p < 0.0001
	Serum	Sepsis = 39	–	–	15.5–49.9	–	–	↑ PAI-1 in patients with DIC, p = 0.016	[34]
		Control = 15			ng/ml
		Age ≥ 18 years
sICAM-1	Plasma	Sepsis = 63	–	–	–	–	–	↑ Severe sepsis ↑ sICAM-1, p < 0.001	[33]
		Severe sepsis = 61	–	–	–	0.15	–	↑ sICAM-1 correlated with SOFA score at 24 h, p < 0.03
		Septic shock = 42					–	↑ sICAM-1 correlate with APACHE-II score, p < 0.05
		Age = 60 ± 17	–	–	–	0.17	–
	Serum	Severe sepsis = 48	–	–	1.297–1787 ng/ml	-	–	↑ sICAM-1 in non-survivors, p < 0.001	[79]
		Septic shock = 54	–	–	–	–	–	↑ sICAM-1, predictor of 90 day-mortality, p < 0.0001
		Age ≥ 18 years	–	–	–	–	–	↑ sICAM-1, septic shock compared to severe sepsis p < 0.01
S100B	Serum	Septic shock = 22	–	–	> 0.15 μg/l	–	–	↑ Delirium was present in 10/22 of the patients (45.5%)	[37]
			–	–	–	–	–	OR: 18.0, for risk of developing delirium S-100β > 0.15 μg/l
			–	–	–	–	0.489	↑ S100 β correlate positively with and IL-6 p = 0.021
	Serum	Sepsis = 104	80.0% and	66.1 and	0.226 and	–	–	↑ S100B cut-of value for day 1 and 3	[36]
		Sepsis-associated encephalopathy = 59	84.44%	69.49%	0.144 μg/l	–	–	↑ S100B in sepsis-associated encephalopathy day 1 to day 3 compared with non- sepsis-associated encephalopathy, p < 0.001
		non- sepsis-associated encephalopathy = 45	–	–	–	–	0.728 and 0.819	↑ S100B on days 1 and 3 to predict sepsis-associated encephalopathy
			–	–	–	–	0.61	↑ S100B on day 1 to predict 180 day-mortality
			84.44%	69.49%	0.529 μg/l	–	0.731	↑ S100B on day 3 to predict 180 day-mortality
			93.33%	50.00%	0.266 μg/l
	Serum	Sepsis = 21	–	–	–	–	0.082, 0.082,	↑ S100B did not correlate with GCS, EEG pattern, or SOFA scores	[108]
	Serum	Age = 68.7	–	–	–	–	and 0.124		[108]
E-selectin	Plasma	Sepsis = 63	–	–	–	–	0.77	↑ Predict mortality	[33]
		Severe sepsis = 61	–	–	–	–	–	↑ Severe sepsis ↑ sE-selectin, p < 0.001
		Septic shock = 42	–	–	–	0.27	–	↑ sE-selectin correlated with SOFA score at 24 h, p < 0.0001
		Age = 60 ± 17	–	–	–	0.31	–	↑ sE-selectin correlated with APACHE-II score, p < 0.0001
sFlt-1	Plasma	Sepsis = 63	–	–	–	-	0.85	↑ sFlt-1 to predict mortality, p < 0.05	[33]
		Severe sepsis = 61	–	–	–	0.36	–	↑ sFlt-1 associated with organ dysfunction
		Septic shock = 42	–	–	–	0.63	–	↑ sFlt-1 correlation with ↑ IL-6, p < 0.0001
		Age = 60 ± 17	–	–	–	0.6	–	↑ sFlt-1 correlated with SOFA score at 24 h, p < 0.0001
			–	–	–	0.64	–	↑ sFlt-1 correlated with APACHE-II score, p < 0.0001
sVCAM-1	Plasma	Sepsis = 63	–	–	–	–	0.78	↑ Predict mortality	[33]
		Severe sepsis = 61	–	–	–	–	–	↑ Severe sepsis ↑ sVCAM-1, p < 0.002
		Septic shock = 42	–	–	–	0.45	–	↑ sE-selectin correlated with SOFA at 24 h, p < 0.0001
		Age = 60 ± 17	–	–	–	0.38	–	↑ sVCAM-1 correlated with APACHE-II s, p < 0.0001
	Serum	Severe sepsis = 48	–	–	369–467 µg/l	–	–	↑ sVCAM in non-survivors, p < 0.001	[79]
		Septic shock = 54	–	–	–	–	–	↑ sVCAM, predictor of 90 day-mortality, p < 0.0001
		Age ≥ 18 years	–	–	–	–	–	↑ sVCAM, septic shock compared to severe sepsis, p < 0.01
	Plasma	SIRS = 943	–	–	–	–	–	↑ s-VCAM was associated with an increased risk of shock. OR: 1.63	[81]
		Sepsis = 330						↑ sVCAM-1 non-survivor, p < 0.001
		Shock = 216	–	–	819 pg/ml	–	–
		Pneumonia = 169
		Others = 152
		Age = 55.1 ± 16.1
		♂ 63.9%
ZO-1	Serum	Sepsis = 11	–	–	–	–	–	↑ ZO-1 in severe sepsis and septic shock compared to sepsis, p < 0.05	[31]
		Severe sepsis = 18	–	–	–	–	–	↑ ZO-1 in non-survivors compared with survivors, p < 0.01
		Septic shock = 22	–	–	–	–	–	↑ ZO-1 in MODs group
			–	–	–	–	0.502 and 0.380	↑ ZO-1 was positively correlated with SOFA and APACHE-II scores, p < 0.001 and p < 0.006
	Brain tissue autopsies	Sepsis = 47	–	–	–	–	–	ZO-1 is absent from the endothelial cells in the cerebrum and endothelium	[32]
Gut permeability markers
Citrulline	Plasma	Septic shock = 16	–	–	–	–	–	Citrulline was positively correlated with plasma arginine (r² = 0.85) and glutamine (r² = 0.90) concentrations in both groups, and significantly inversely correlated with CRP (r² = 0.10)	[109]
		(Survivors = 8						↓ Citrulline in patients with digestive bacterial translocation
		Age = 60 ± 16.5
		Non-survivor = 8
		Age = 62.9 ± 18.5	–	–	–	–	–
	Plasma	Sepsis/ARDS = 44	–	–	–	–	–	↓ Citrulline in all patients	[83]
		Sepsis/NO ARDS = 91	–	–	6 and 10.1 uM	–	–	↓ ARDS compared to the no ARDS group, p = 0.002
		Age = 55 ± 16	–	–	–	–	–	Citrulline levels were associated with ARDS
I-FABP	Serum	Sepsis = 30	–	–	27.46 and 36.95 μg/l	–	–	↑ I-FABP sepsis and septic shock group, p < 0.01	[40]
		Septic shock = 30			–			↑ I-FABP no difference between survivors and non-survivors
		Control = 20	–	–		–	–
Zonulin	Plasma	Sepsis = 25	–	–	6.61 ng/ml	–	–	↑ Zonulin sepsis compared to post-surgical and control groups, p = 0.008	[39]
		Post-surgical = 18	–	–	–	–	–	No difference between survivors and non-survivors, p = 0.305
		Control = 20	–	–	–	–	0.01, − 0.46, − 0.19, and 0.10	↑ Zonulin, no correlation with CRP, APACHE-II, SAPSII, SOFA, p = 0.997, p = 0.077, p = 0.491, and p = 0.671, subsequently
D-lactic acid	Serum	Sepsis = 30	–	–	15.32 and 27.95 mg/l	–	–	↑ D-lactic acid sepsis and septic shock groups, p < 0.01	[40]
		Septic shock = 30	–	–		–	–	↑ D-lactic acid is no different between survivors and non-survivors
		Control = 20
Non-coding RNAs
Lnc-MALAT1	Plasma	Sepsis = 196	–	–	–	–	0.866	↑ Lnc‐MALAT1/miR‐125a axis in sepsis patients	[41]
		Age = 58.2 ± 11.2	–	–	–	–	–	↑ Lnc‐MALAT1 relative expression in sepsis patients
		Control = 196	–	–	–	–	–	Lnc-MALAT1/miRNA-125a axis discriminates sepsis patients from healthy controls and exhibits a positive association with general disease severity, organ injury, inflammation level, and mortality in sepsis patients
		Age = 57.1 ± 12.1
	Plasma	Sepsis = 152	68.50%	65.90%	–	–	0,674 (ARDS	↑ lnc-MALAT1 correlates with raised ARDS risk, disease severity, and increased mortality in septic patients	[42]
		Age = 59.7 ± 11.2	38.30%	88.60%	–	–	0.651	High mortality in sepsis patients
			–	–	–	–	–	Lnc-MALAT1 expression was positively correlated with inflammatory factor levels (CRP, PCT, TNF-α, IL-1β, IL-6, and IL-17) in septic patients
	Plasma	Sepsis = 120	–	–	–	–	0.91	↑ lnc-MALAT1 in septic patients, distinguishing patients with sepsis from control	[110]
		Control = 60	–	–	–	–	0.836	Septic shock patients compared to patients without septic shock
			–	–	–	–	0.886	Non-survivors compared to surviving patients
			–	–	–	–	–	↑ Lnc-MALAT1 expression was an independent risk factor for sepsis, septic shock, and poor prognosis
lnc-MEG3	Plasma	Sepsis = 219	–	–	–	–	0,887	↑ lnc‐MEG3 expression predicting elevated sepsis risk	[43]
		Control = 219	–	–	–	–	0.934	lnc-MEG3/miR-21 axis predicting elevated sepsis risk
		Age = 56.5 ± 10.3	–	–	–	–	0.801	miR-21 was predicting reduced sepsis risk
			–	–	–	–	0.704	lnc‐MEG3 predicting 28‐day mortality risk
			–	–	–	–	0.669	lnc‐MEG3/miR‐21 axis predicting 28‐day mortality risk
			–	–	–	–	–	↑ lnc-MEG3/miR-21 axis, while ↓ miR-21 expression was decreased in sepsis patients
							-	lnc-MEG3 expression and lnc‐MEG3/miR‐21 axis positively correlated, whereas miR‐21 expression negatively correlated with APACHE-II, SOFA, and inflammatory molecules in sepsis patients
								↑ lnc‐MEG3 relative expression and lnc‐MEG3/miR‐21 axis in deaths than that in survivor
miRNA
miR-125a, miR-125b	Plasma	Sepsis = 120	–	–	–	–	0.557	↔ miR‐125a expression between groups of patients and not differentiate sepsis patients from controls	[84]
		Control = 120	–	–	–	–	0.658	↑ miR-125b in sepsis patients and can distinguish sepsis patients from control healths
		59.1 ± 12.1	–	–	–	–	–	Positive correlation between miR‐125a and miR‐125b in sepsis patients and controls
			–	–	–	–	–	miR-125a was not correlated with APACHE-II or SOFA score, while miR-125b was positively associated with both scores
			–	–	–	–	–	↓ miR-125b in survivors compared with non‐survivors
			–	–	–	–	–	↑ miR-125b, but not miR‐125a, is correlated with ↑ disease severity, inflammation, and ↑ mortality in sepsis patients
	Plasma	Sepsis = 126	–	–	–	–	0.817	↓ miR-125a good predictive values for sepsis risk	[85]
		Control = 125	–	–	–	–	0.843	↑ lnc‐ANRIL/miR‐125a axis for sepsis risk
		Age = 56.6 ± 13	–	–	–	–	0.745	↓ miR‐125a expression in deaths than those in survivors
			–	–	–	–	0.785	↑ lnc‐ANRIL/miR‐125a differentiating deaths from survivors
			–	–	–	–	–	lnc-ANRIL/miR-125a axis positively correlated, and miR-125a was negatively associated with disease severity and inflammation in sepsis patients
	Plasma	Sepsis = 150	–	–	–	–	0.749 and 0.839	↑ miR-125a and miR-125b distinguish sepsis patients from controls	[111]
		Age = 56.9 ± 10.3	–	–	–	–	0.588	miR-125a to predict 28-day mortality risk
		Control = 150	–	–	–	–	0.699	miR-125b had a potential value in predicting elevated 28-day mortality risk
		Age = 55.1 ± 11.4	–	–	–	–	–	miR-125a failed to predict the 28-day mortality risk in sepsis patients
			–	–	–	–	–	1. The predictive value of miR‐125b for sepsis risk
			–	–	–	–
								miR‐125a and miR‐125b relative expressions were positively associated with disease severity in sepsis patients
	Plasma	Sepsis = 196	–	–	–	–	–	↑ lnc‐MALAT1/miR‐125a axis in sepsis patients, p < 0.001	[41]
		Age = 58.2 ± 11.2	–	–	–	–	0.931	lnc-MALAT1/miRNA-125a axis discriminates sepsis patients from control
		Control = 196	–	–	–	–	0.866	lnc-MALAT1 discriminates sepsis patients from control
		Age = 57.1 ± 12.1
Membrane receptors, cell proteins, and metabolites
CD64	Blood	Sepsis = 119	–	–	–	–	–	↑ nCD64 and SOFA score in the sepsis compared to control p < 0.05	[46]
		Septic shock = 32	–	–	4.1, 9, and 2.2 MFI	–	–	↑ Sepsis and septic shock compared to control p < 0.001
		Control = 20	–	–	–	–	0.879	nCD64 in bacterial infection
			–	–	–	–	0.888	↑ AUC of nCD64 combined with SOFA than that of any other parameter alone or in combination
			–	–	–	–	0.85	CD64 for predicting death
			–	–	–	–	0.916	Combination of nCD64 and SOFA score
			–	–	4.1 versus 8.9 MFI	–	–	↑ nCD64 survivors versus non-survivors p < 0.001
	Blood	Sepsis = 20	0.82, 0.67 and 0.67	0.67, 0.76, and 0.76	< 90.40, < 3.01, and < 0.825	–	0.843, 0.824, and 0.804	↑ CD64, ↓CD13, and ↓HLA-DR predict mortality in septic patients	[45]
		Age = 54.35 ± 17.97
		Control = 20
		Age = 51.55 ± 13.37
CD68	Brain	Septic shock = 16	–	–	–	–	–	↑CD68 in the hippocampus (1.5 fold), putamen (2.2 fold), and cerebellum (2.5 fold) in patients with sepsis than control patients	[86]
		Age = 8.9–71.7
		Control = 15
		Age = 65.2–87.4
NFL	CSF and plasma	Sepsis = 20	–	–	1723.4, 1905.2	–	–	Day 1 – sepsis versus control p > 0.05	[87]
		Age = 66.7 ± 14.0	–	–	2753.1, 2208.0	–	–	Day 3 – sepsis versus control p > 0.05
		Control = 5	–	–	5309.6, 3701.3 pg/ml	–	–	Day 7 – sepsis versus control p > 0.05
		Age = 61.2 ± 24.7	–	–	–	–	–	↑ NFL in patient septic compared to control from day 1 p = 0.0063
			–	–	–	–	–	↑ NFL patients with sepsis-associated encephalopathy p = 0.011
			–	–	–	–	–	↑ NFL correlated with the severity of sepsis-associated encephalopathy p = 0.022
			–	–		–	–	↑ NFL at CSF in non-survivors compared to survivors p = 0.012
NFH	CSF and plasma	Sepsis = 20	–	–	17.6, 100.3	-	-	Day 1 – sepsis versus control p > 0.05	[87]
		Age = 66.7 ± 14	–	–	18.9, 163.1	–	–	Day 3 – sepsis versus control p > 0.05
		Control = 5	–	–	164.3, 519.9	–	–	Day 7 – sepsis versus control p = 0.016
		Age = 61.2 ± 24.7	–	–	ng/ml	–	–	↑ NFH from day 1 in septic patients p = 0.043
NSE	Serum	Sepsis/ sepsis-associated encephalopathy = 48	–	–	24.87 and 15.49 ng/ml	–	–	↑ NSE in sepsis-associated encephalopathy group versus no- sepsis-associated encephalopathy group p = 0.003	[80]
		Age = 56 ± 16 Sepsis/non- sepsis-associated encephalopathy = 64			24.15 ng/ml			Diagnostic of sepsis-associated encephalopathy
		Age = 52 ± 17	82.80%	54.20%	–	–	0.664	↔ NSE, sepsis-survivors versus sepsis-non-survivors p = 0.108
			–	–		–	–
	Plasma	Sepsis = 124	–	–	> 12.5 ug/l	–	–	23.3%, increased risk of 30-day mortality, p = 0.006, and a 29.3% increased risk of delirium p = 0.005	[88]
	Plasma	Mean age = 52–71	–	–	–	–	–	↑ NSE is associated with mortality p = 0.003, and delirium in critically ill septic patients p < 0.001	[88]
	CSF and plasma	Sepsis/ sepsis-associated encephalopathy = 12	–	–	Eight versus 3.8 ng/ml	–	–	↑ CSF NSE in sepsis group compared to controls p < 0.05	[112]
		Control = 21						↔ Plasma NSE sepsis group versus control group
		Mean age = 67.8 ± 1 2.1	–	–	–	–	–
Presepsin	Blood	Sepsis = 33	90.70%	98.60%	407 pg/ml	–	0.954	↑ Presepsin in sepsis patients compared to SIRS group p < 0.05	[48]
		Severe sepsis = 24						↑ Presepsin and APACHE-II score in severe sepsis group than sepsis group p < 0.05
		Septic shock = 15	–	–	–	–	–	↑ Presepsin and APACHE-II score in septic shock group compared to severe sepsis group p < 0.05
		SIRS = 23
		Normal = 20	–	–	–	–	–
		Mean age = 62.1
TREM-1	Serum	Severe sepsis = 34	–	–	129 pg/ml versus 105 pg/ml	–	–	↑ TREM-1 levels in septic shock compared to severe sepsis	[89]
		Septic shock = 53	–	–	–	–	–	↔ TREM-1 did not differentiate between septic shock and severe sepsis
		Age = 2 mo to 16 years	56%	60%	116.47 pg/ml	–	0.62	Predict septic shock
			52%	71%	116.47 pg/ml	–	0.63	Predict mortality
			–	–	–	–	–	↔ TREM-1 non-survivors versus survivors
	Serum	SIRS = 38	73.30%	71.10%	≥ 133 pg/ml	–	–	sTREM-1 cut-off for sepsis	[113]
		Sepsis = 52	–	–	–	–	–	↑ sTREM-1 in sepsis group p = 0.001
		Age = 20 to 92	–	–	–	–	–	↑ sTREM-1 in the patients with positive blood culture p = 0.002
	Plasma and leukocytes	Septic shock = 60 Postoperative = 30	100%	98.30%	30.0 pg/ml	–	–	↑ sTREM-1 plasma in septic shock compared to control and postoperative groups p < 0.05	[91]
		Control = 30	–	–	–	–	–	↑ sTREM-1 compared with postoperative group p < 0.05
			–	–	–	–	0.955	↑ TREM-1 expression on human monocytes of a septic shock compared to control and postoperative groups p < 0.05
Peptide precursor of the hormone and hormone
MR-proADM	Plasma	Sepsis/bacterial isolate = 39	78%	74.20%	≥ 1.5	–	0.82	↑ MR-proADM sepsis versus control p < 0.0001	[92]
		Sepsis w/bacterial isolate = 23	80%	89.36%	≥ 1.70	–	0.92	↑ MR-proADM septic shock versus control p < 0.0001
		Septic shock = 47	77.40%	59.60%	> 3.00	–	0.7	↑ MR-proADM septic shock versus sepsis p < 0.0001
		Control = 50	–	–	4.37 versus 2.34 nmol/l	–	–	↑ MR-proADM, non-survivor versus survivor p < 0.0001
Bio-ADM		Sepsis = 632	–	–	–		–	Median sepsis patients = 74 pg/mL; septic shock = 107 pg/mL, and 29 pg/mL in non-septic patients	[53]
		Septic shock = 267	–	–	–			Mortality in sepsis patients OR of 1.23
		Non-septic = 1235	–	–	–		–	↑ Dialysis: OR 1.97 in sepsis patients
			–	–	70 pg/mL			↑ bio-ADM ↑ Use of vasopressors, OR 1.33
			–	–	108 pg/mL		–	Survivors and non-survivors in sepsis
			–	–	–			Youden’s index derived threshold of performed better
			–	–			–	↑ bio-ADM non-survivors
							–
							–
							–
PCT	Serum	Sepsis = 59	–	–	–	–	–	↑ PCT p < 0.0005	[66]
		Severe sepsis/septic shock = 71	–	–	0.67 versus 3.81	–	–	Survivor versus non-survivor at seven days
		Mean age = 80	–	–	0.48 versus 1.82 ng/mL	–	–	Survivor versus non-survivor at 30 days
	Serum	SIRS = 38	65.79%	67.33%	1.57 ng/ml	–	–	PCT cut-off for sepsis	[113]
		Sepsis = 52	–	–	–	–	–	↑ PCT in sepsis group, p = 0.01
		Age = 20 to 92
	Serum	Sepsis = 79	–	–	–	–	–	↑ PCT concentrations in patients with sepsis and infection	[114]
		Age = newborn to 12						↓ PCT concentrations with antibiotic treatment
		Control = 21	–	–		–	–
		Age = newborn to 10
	Blood	Sepsis = 119	–	–	17.1, 1.8, and 0.04 ng/ml	–	–	↑ PCT septic shock and sepsis compared to the control group p < 0.001	[46]
		Septic shock = 32	–	–	1.8 and 9.2 ng/ml	–	–	↑ PCT levels in survivors versus non-survivors p > 0.001
		Control = 20
	Blood	Sepsis = 33	90.70%	98.60%	407 pg/ml	–	0.874	↑ PCT sepsis patients compared to SIRS group p < 0.05	[48]
		Severe sepsis = 24	–	–	–	–	–	↑ PCT and APACHEII score in severe sepsis group compared to sepsis group p < 0.05
		Septic shock = 15
		SIRS = 23
		Normal = 20
		Mean age = 62.1
	Plasma	Sepsis and shock septic = 1089						↔ There was no statistic difference in the primary outcome regarding PCT-guidance 27.9% versus no PCT-guidance 22.9% to predict mortality p = 0.18	[61]
		PCT-guidance n = 279						↔ PCT-guidance versus no PCT-guidance there was no statistic difference in 28-day mortality, 25.6% versus 28.2% p = 0.34
		No PCT-guidance n = 267
	Serum	Severe sepsis = 34	–	–	129 pg/ml versus 105 pg/ml	–	–	↔ PCT did not differentiate septic shock from severe sepsis	[89]
		Septic shock = 53
		Age = 2 mo to 16 years
NT-proBNP	Serum	Sepsis = 60	–	–	1.209 ng/l	–	–	↑ NT-proBNP level at 24 h after sepsis diagnosis	[55]
		Severe sepsis = 89	–	–	–	–	–	↑ NT-proBNP levels at 24 h after sepsis onset were associated with ↓ SPPB scores at 12 months p < 0.05, and ↓ handgrip strength at six and 12-month follow-up p < 0.001
		Septic shock = 47
		Age = 59.1 ± 15.1
	Plasma	Sepsis = 142			4 (2.6–8.8) versus 8.2 nmol/L (5.2–12.6)		-	↑ NT-proBNP levels in non-survivors compared with survivors p < 0.01. ↔ CRP did not change in survivors and non-survivors	[52]
		Septic shock = 947					-	↑ NT-proBNP prediction of 28-day mortality in total population, sepsis group, and shock septic group, respectively
							0.73, 0.73, and 0.72
Neutrophil, cells, and related biomarkers
Lactate	Plasma	Sepsis = 59	–	–	–		–	↑ Lactate p < 0.0005	[66]
		Severe sepsis/septic shock = 71	–	–	1.7 versus 3.4		–	Survivor versus non-survivor at seven days
		Mean age = 80	–	–	1.6 versus 2.2		–	Survivor versus non-survivor at 30 days
			–	–	mmol/l		0.79 and 0.77	Predictors of mortality at 7 and 30 days p = 0.001
	Serum	Non- sepsis-associated encephalopathy = 2513 Sepsis-associated encephalopathy = 2474	–	–	–	–	–	↑ Lactate predicted 30-day mortality of patients with sepsis-associated encephalopathy, OR: 1.19 p < 0.0005	[93]
	Blood	Sepsis = 33	90.70%	98.60%	407 pg/ml	–	0.859 and 0.723	↑ Lactate and APACHE-II score in severe sepsis group compared to sepsis group p < 0.05	[48]
		Severe sepsis = 24	–	–	–	–	–	↑ APACHE-II score and lactate in septic shock group when compared with severe sepsis group p < 0.05
		Septic shock = 15
		SIRS = 23
		Normal = 20
		Mean age = 62.1
	Serum	Severe sepsis = 34	–	–	–	–	–	↔ Lactate did not differentiate septic shock from severe sepsis	[89]
		Septic shock = 53
		Age = 2 mo to 16 years
MPO	Plasma	Sepsis = 957	–	–	128.1 ng/ml	–	–	↑ MPO day 1 and progressively decreased until day 7	[94]
MPO	Plasma	Sepsis = 957	–	–	–	–	–	↑ MPO increase on days on days 1, 2, and 7 in 90-day non-survivors p < 0.003, p = 0.03, and p = 0.001	[94]
		Septic shock = 55	–	–	–	–	–	↑ MPO-DNA and cf-DNA in patients with septic shock on day 1 p < 0.01	[95]
		Control = 13	–	–	–	–	–	↑ MPO-DNA on days 3 and 7 of sepsis was associated with 28-day mortality p < 0.01
		Mean age = 68	–	–	–	0.303 and 0.434	–	↑ MPO-DNA on day 3 and 7 positive correlation with SOFA score p = 0.04 and p = 0.03, subsequently
		♂ = 71%
Resistin	Plasma	Sepsis = 957	–	–	192.9 ng/ml	–	–	↑ Resistin on day one and progressively decreased until day 7	[94]
		Mean age = 70	–	–	–	–	–	↑ Resistin increase on days 1, 2, and 7 in 90-day non-survivors p < 0.001
		♂ = 60%
	Serum	Sepsis = 50	72%, 80%, and 100%	82%, 95%, and 100%	5.2, 6.1, and 7,5 ng/ml	–	–	↑ Resistin levels on day 1, 4, and 7	[115]
		Patient without sepsis = 22	–	–	–	–	0.864, 0.987, and 0.987	↑ Resistin levels on days 1, 4, and 7 were associated with sepsis
		Control = 25
		Age ≤ 12
	Serum	Sepsis = 60	–	–	36.45	–	–	↑ Resistin in sepsis/septic shock groups p = 0.001	[96]
		Septic shock = 42	–	–	48.13 versus 31.58	–	–	↑ Resistin levels in non-survivors versus Survivors on day 1 and 7 p < 0.001 and p < 0.001
		Control = 102	–	–	46.20 versus 25.22	–	–	↑ Resistin septic shock versus sepsis on day 1 and 3 p < 0.001 and p < 0.001
					40.8 versus 33.4
					37.1 versus 27.4
					µg/l
Soluble receptors
sPD-L1	Serum	Sepsis = 483	–	–	0.16 ng/ml	–	–	↑ sPD-L1 immunosuppression phenotype, ↑ risk of hospital readmission and mortality, OR = 8.26	[22]
		Mean age = 60.5						↑ sPD-L1, 45 (46.4%) at 3 months, 40 (44.9%) at 6 months, and 44 (49.4%) at 12 months
		♂ 54.9%	–	–	–	–	–	↑ sPD-L1 to predict 28-day mortality ≅ APACHE-II and SOFA scores
			–	–	–	–	–
	Serum	Sepsis = 91	–	–	2.09 ng/ml	–	–	↑ sPD-L1 and sPD-1 in septic patients p = 0.0001	[68]
		Control = 29	–	–	–	–	–	↑ sPD-L1 increased in non-survivors p < 0.05
			–	–	–	–	0.71	↑ sPD-L1 level to predict 28-day mortality
suPAR	Serum	Sepsis = 59	–	–	–	–	–	↑ suPAR, p < 0.0005	[66]
		Severe sepsis/septic shock = 71	–	–	6.9 versus 9.8	–	–	Survivor versus non-survivor at seven days
		Mean age = 80	–	–	6.4 versus 9.3	–	–	Survivor versus non-survivor at 30 days
			–	–	ng/ml		0.72 and 0.77	Predictors of mortality at 7 and 30 days p = 0.006
			–	–	–	–	–	↓ suPAR from day 1 to day seven sepsis and severe sepsis/septic shock p < 0.0005
	Serum	Sepsis = 60	–	–	13	–	–	↑ suPAR in sepsis and septic shock	[96]
		Septic shock = 42	–	–	10.5 versus 14.1	–	–	↑ suPAR in septic shock compared with sepsis on day one but not on day 7 p < 0.04 and p = 0.68, subsequently
		Control = 102			11.3 versus 12.9 μg/l
sTNFR-1	Plasma	SIRS = 943	–	–	7719 versus 18,197	–	–	↑ sTNFR-1 in non-survivor versus survivor, p < 0.001	[81]
		Sepsis = 330	–	–	pg/ml	–	–	↑ sTNFR-1 sepsis compared to SIRS p < 0.001
		Shock = 216
		Pneumonia = 169
		Others = 152
		Age = 55.1 ± 16.1
		♂ 63.9%
	Plasma	No delirium = 47	–	–	3.843 and 10.250 pg/ml	–	–	↑ sTNFR1 and sTNFR2 delirium cutoff p = 0.005	[98]
		Delirium = 31	–	–	–	–	–	↑ sTNFR1 and sTNFR2 in delirium group compared with non-delirium p = 0.005, and p = 0.003, subsequently
								OR: 18 to sTNFR1, p = 0.004 and OR: 51 to
								STNFR2, p = 0.006
			–	–	–	–	–
Lipoproteins
LDL	Serum	Sepsis = 594	–	–	–	–	–	Risk of sepsis, OR, 0.86, p = 0.001and admission to the ICU, OR, 0.85; p = 0.008; but not hospital mortality, OR,	[99]
								↓Quartile greater risk of sepsis; OR, 1.48; and admission to the ICU, OR, 1.45, versus highest quartile
								↔ When comorbidities were considered
HDL	Serum	Sepsis = 63	–	–	–	–	–	↓ HDL in non-survivors on days 1 to 4	[100]
		Mean age = 72	–	–	–	–	0.84	Predicts mortality within 30 days
			80%	92%	20 mg/dl	–	–	83% accuracy to predict 30-day overall mortality
			–	–	–	–	–	HDL < 20 mg/dl increases attributable mortality, risk of prolonged ICU stay, and hospital-acquired infection rate
	Plasma	Suspected sepsis = 200	0.690	0.716	30.9 mg/dl	–	0,749	MODS predictor	[101]
			0.699	0.857	25,1 mg/dl	–	0,818	Mortality in 28 days
			–	–	< 25.1 mg/dl	–	–	↑ Mortality, p < 0.0001 in 28 days and p = 0.0007 in 90 days
			–	–	–	–	–	74% of patients with HDL < 25.1 mg/dl required ICU compared to 35% above cutoff; development of severe acute renal dysfunction was 47% versus 21%, respectively; multiple organ dysfunction was 60% versus 25%; and mechanical ventilation was 53% versus 21%
			–	–	–	–	–	↓ HD, the 28-day mortality is more than ten-fold higher (17.6% versus 1.5%) and a mean of 6.2 fewer days without mechanical ventilation and vasopressor support
T-chol	Serum	Sepsis = 136	–	–	–	–	–	↓ T-chol associated with risk of death in septic patients p < 0.05	[102]

Ang-1 angiopoietin-1, Ang-2 angiopoietin-2, APACHE-II acute physiology and chronic health evaluation II, ARDS acute respiratory distress syndrome, AUC area under the curve, BBB blood–brain barrier, BMVEC brain microvascular endothelial cells, CD cluster of differentiation, CLDN-5 claudin-5, CRP C reactive protein, CSF cerebrospinal fluid, DAMPs damage-associated molecular patterns, DIC disseminated intravascular coagulation, EEG electroencephalography, GCS Glasgow coma scale, HDL high-density lipoprotein, HLA-DR human leukocyte antigen, HMGB1 high mobility group box 1, hsCRP high-sensitivity C reactive protein, I-FABP intestinal fatty acid binding protein, IL interleukin, LDL low-density lipoprotein, lnc-ANRIL long non-coding antisense non-coding RNA in the INK4 locus, lnc-MALAT1 long non-coding metastasis-associated lung adenocarcinoma transcript 1, lnc-MEG3 long non-coding RNA maternally expressed gene 3, lncRNA long non-coding RNA, MCP-1 monocyte chemoattractant protein-1, miR-125a micro RNA-125a, miR-125b micro RNA-125b, MODS multiple organ dysfunction syndrome, MOF multiple organ failure, MPO myeloperoxidase, MR-proADM mid-regional pro adrenomedullin, NFL neurofilament light, NfH neurofilament heavy, NSE neuron specific enolase, NT-proBNP N-terminal pro-brain natriuretic peptide, OCLN occludin, OR odds ratio, PAI-1 plasminogen activator inhibitor 1, PCT procalcitonin, PTX-3 pentraxin-3, RNA ribonucleic acid, S100B calcium-binding protein B, sE-Selectin soluble E-selectin, sFlt-1 soluble fms-like tyrosine kinase 1, sICAM-1 soluble intercellular adhesion molecule 1, SIRS systemic inflammatory response syndrome, SOFA sequential organ failure assessment, sPD-1 soluble programmed death protein 1, sPD-L1 soluble programmed death ligand 1, SPPB short physical performance battery, sTNFR1 soluble tumor necrosis factor receptor type 1, sTNFR2 soluble tumor necrosis factor receptor type 2, sTREM-1 soluble triggering receptor expressed on myeloid cells 1, suPAR soluble form of the urokinase plasminogen activator receptor, sVCAM-1 soluble vascular cell adhesion molecule 1, T-chol total cholesterol, TNF-α tumour necrosis factor alpha, TREM-1 triggering receptor expressed on myeloid cells-1, VLA-3/a3β1 integrin alpha 3 beta 1, ZO-1 zonula-occluden 1). ↑ increase, ↓ decrease, ↔ no difference

Conclusion

Despite significant advances in treating septic patients, this disease continues to be associated with high mortality rates and high long-term cognitive dysfunction. Extensive research in the area is being performed to validate biomarkers, facilitate sepsis diagnosis, and allow an early intervention that, although primarily supportive, can reduce the risk of death. Sepsis sometimes shows a hyperinflammatory response pattern and may be followed by an immunosuppressive phase, during which multiple organ dysfunction is present. A biomarker or a panel of biomarkers could be a new avenue to predict, identify, or provide new approaches to treat sepsis.

Acknowledgements

This work was supported by the Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), USA (T.B.); the Graduate Program in Health Sciences, University of Southern Santa Catarina (UNESC) (T.B., JSG, and FDP), Brazil; the Alzheimer's Association and U.S. National Institute of Health/National Institute on Aging (NIH/NIA (T.B.).

Declarations

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Arina P, Singer M. Pathophysiology of sepsis. Curr Opin Anaesthesiol. 2021;34(2):77–84.PubMedCrossRef

Vincent JL, Martin GS, Levy MM. qSOFA does not replace SIRS in the definition of sepsis. Crit Care (Lond, Engl). 2016;20(1):210.CrossRef

Yende S, Kellum JA, Talisa VB, Peck Palmer OM, Chang CH, Filbin MR, Shapiro NI, Hou PC, Venkat A, LoVecchio F, et al. Long-term host immune response trajectories among hospitalized patients with sepsis. JAMA Netw Open. 2019;2(8):e198686.PubMedPubMedCentralCrossRef

Barichello T, Generoso JS, Dominguini D, Córneo E, Giridharan VV, Sahrapour TA, Simões LR, Rosa MID, Petronilho F, Ritter C, et al. Postmortem evidence of brain inflammatory markers and injury in septic patients: a systematic review. Crit Care Med. 2021. https://doi.org/10.1097/CCM.0000000000005307.CrossRef

Kumar S, Ingle H, Prasad DV, Kumar H. Recognition of bacterial infection by innate immune sensors. Crit Rev Microbiol. 2013;39(3):229–46.PubMedCrossRef

Heckenberg SG, Brouwer MC, van de Beek D. Bacterial meningitis. Handb Clin Neurol. 2014;121:1361–75.PubMedCrossRef

Sellner J, Täuber MG, Leib SL. Pathogenesis and pathophysiology of bacterial CNS infections. In: Karen LR, Allan RT, editors. Handbook of clinical neurology, vol. 96. Amsterdam: Elsevier; 2010. p. 1–16.

Mook-Kanamori BB, Geldhoff M, van der Poll T, van de Beek D. Pathogenesis and pathophysiology of pneumococcal meningitis. Clin Microbiol Rev. 2011;24(3):557–91.PubMedPubMedCentralCrossRef

10.

Gong T, Liu L, Jiang W, Zhou R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol. 2020;20(2):95–112. https://doi.org/10.1038/s41577-019-0215-7.CrossRefPubMed

11.

Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science (New York, NY). 2010;327(5963):291–5.CrossRef

12.

Wiersinga WJ, Leopold SJ, Cranendonk DR, van der Poll T. Host innate immune responses to sepsis. Virulence. 2014;5(1):36–44.PubMedCrossRef

13.

Lu B, Wang C, Wang M, Li W, Chen F, Tracey KJ, Wang H. Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: an updated review. Expert Rev Clin Immunol. 2014;10(6):713–27.PubMedPubMedCentralCrossRef

14.

Kigerl KA, de Rivero Vaccari JP, Dietrich WD, Popovich PG, Keane RW. Pattern recognition receptors and central nervous system repair. Exp Neurol. 2014;258:5–16.PubMedPubMedCentralCrossRef

15.

Kataoka H, Kono H, Patel Z, Rock KL. Evaluation of the contribution of multiple DAMPs and DAMP receptors in cell death-induced sterile inflammatory responses. PLoS ONE. 2014;9(8):e104741.PubMedPubMedCentralCrossRef

16.

Generoso JS, Giridharan VV, Lee J, Macedo D, Barichello T. The role of the microbiota-gut-brain axis in neuropsychiatric disorders. Braz J Psychiatry. 2020;10(44462020005021200):1516–4446.

17.

Annane D, Sharshar T. Cognitive decline after sepsis. Lancet Respir Med. 2015;3(1):61–9.PubMedCrossRef

18.

Barichello T, Sayana P, Giridharan VV, Arumanayagam AS, Narendran B, Della Giustina A, Petronilho F, Quevedo J, Dal-Pizzol F. Long-term cognitive outcomes after sepsis: a translational systematic review. Mol Neurobiol. 2019;56(1):186–251.PubMedCrossRef

19.

Erreni M, Manfredi AA, Garlanda C, Mantovani A, Rovere-Querini P. The long pentraxin PTX3: a prototypical sensor of tissue injury and a regulator of homeostasis. Immunol Rev. 2017;280(1):112–25.PubMedCrossRef

20.

McFadyen JD, Zeller J, Potempa LA, Pietersz GA, Eisenhardt SU, Peter K. C-Reactive protein and its structural isoforms: an evolutionary conserved marker and central player in inflammatory diseases and beyond. Subcell Biochem. 2020;94:499–520.PubMedCrossRef

21.

Pierrakos C, Velissaris D, Bisdorff M, Marshall JC, Vincent JL. Biomarkers of sepsis: time for a reappraisal. Crit Care (Lond, Engl). 2020;24(1):287.CrossRef

22.

23.

Caironi P, Masson S, Mauri T, Bottazzi B, Leone R, Magnoli M, Barlera S, Mamprin F, Fedele A, Mantovani A, et al. Pentraxin 3 in patients with severe sepsis or shock: the ALBIOS trial. Eur J Clin Invest. 2017;47(1):73–83.PubMedCrossRef

24.

Song J, Moon S, Park DW, Cho HJ, Kim JY, Park J, Cha JH. Biomarker combination and SOFA score for the prediction of mortality in sepsis and septic shock: a prospective observational study according to the Sepsis-3 definitions. Medicine. 2020;99(22):e20495.PubMedCrossRef

25.

Younger JG, Bracho DO, Chung-Esaki HM, Lee M, Rana GK, Sen A, Jones AE. Complement activation in emergency department patients with severe sepsis. Acad Emerg Med Off J Soc Acad Emerg Med. 2010;17(4):353–9.CrossRef

26.

Abe T, Kubo K, Izumoto S, Shimazu S, Goan A, Tanaka T, Koroki T, Saito K, Kawana R, Ochiai H. Complement activation in human sepsis is related to sepsis-induced disseminated intravascular coagulation. Shock (Augusta, Ga). 2020;54(2):198–204.CrossRef

27.

Matsumoto H, Ogura H, Shimizu K, Ikeda M, Hirose T, Matsuura H, Kang S, Takahashi K, Tanaka T, Shimazu T. The clinical importance of a cytokine network in the acute phase of sepsis. Sci Rep. 2018;8(1):13995.PubMedPubMedCentralCrossRef

28.

Larsson A, Tydén J, Johansson J, Lipcsey M, Bergquist M, Kultima K, Mandic-Havelka A. Calprotectin is superior to procalcitonin as a sepsis marker and predictor of 30-day mortality in intensive care patients. Scand J Clin Lab Invest. 2020;80(2):156–61.PubMedCrossRef

29.

Matsuura R, Komaru Y, Miyamoto Y, Yoshida T, Yoshimoto K, Hamasaki Y, Nangaku M, Doi K. Different biomarker kinetics in critically ill patients with high lactate levels. Diagnostics (Basel, Switzerland). 2020;10(7):454.

30.

Barichello T, Generoso JS, Collodel A, Petronilho F, Dal-Pizzol F. The blood-brain barrier dysfunction in sepsis. Tissue Barriers. 2021;9(1):1840912.PubMedCrossRef

31.

Zhao GJ, Li D, Zhao Q, Lian J, Hu TT, Hong GL, Yao YM, Lu ZQ. Prognostic value of plasma tight-junction proteins for sepsis in emergency department: an observational study. Shock. 2016;45(3):326–32.PubMedCrossRef

32.

Erikson K, Tuominen H, Vakkala M, Liisanantti JH, Karttunen T, Syrjälä H, Ala-Kokko TI. Brain tight junction protein expression in sepsis in an autopsy series. Crit Care. 2020;24(1):385.PubMedPubMedCentralCrossRef

33.

Skibsted S, Jones AE, Puskarich MA, Arnold R, Sherwin R, Trzeciak S, Schuetz P, Aird WC, Shapiro NI. Biomarkers of endothelial cell activation in early sepsis. Shock. 2013;39(5):427–32.PubMedPubMedCentralCrossRef

34.

Ikeda M, Matsumoto H, Ogura H, Hirose T, Shimizu K, Yamamoto K, Maruyama I, Shimazu T. Circulating syndecan-1 predicts the development of disseminated intravascular coagulation in patients with sepsis. J Crit Care. 2018;43:48–53.PubMedCrossRef

35.

Bloomfield SM, McKinney J, Smith L, Brisman J. Reliability of S100B in predicting severity of central nervous system injury. Neurocrit Care. 2007;6(2):121–38.PubMedCrossRef

36.

Wu L, Feng Q, Ai ML, Deng SY, Liu ZY, Huang L, Ai YH, Zhang L. The dynamic change of serum S100B levels from day 1 to day 3 is more associated with sepsis-associated encephalopathy. Sci Rep. 2020;10(1):7718.PubMedPubMedCentralCrossRef

37.

Erikson K, Ala-Kokko TI, Koskenkari J, Liisanantti JH, Kamakura R, Herzig KH, Syrjälä H. Elevated serum S-100β in patients with septic shock is associated with delirium. Acta Anaesthesiol Scand. 2019;63(1):69–73.PubMedCrossRef

38.

Assimakopoulos SF, Triantos C, Thomopoulos K, Fligou F, Maroulis I, Marangos M, Gogos CA. Gut-origin sepsis in the critically ill patient: pathophysiology and treatment. Infection. 2018;46(6):751–60.PubMedCrossRef

39.

Klaus DA, Motal MC, Burger-Klepp U, Marschalek C, Schmidt EM, Lebherz-Eichinger D, Krenn CG, Roth GA. Increased plasma zonulin in patients with sepsis. Biochem Med (Zagreb). 2013;23(1):107–11.CrossRef

40.

Zhang X, Liu D, Wang Y, Yan J, Yang X. Clinical significance on serum intestinal fatty acid binding protein and D-lactic acid levels in early intestinal injury of patients with sepsis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019;31(5):545–50.PubMed

41.

Liu W, Geng F, Yu L. Long non-coding RNA MALAT1/microRNA 125a axis presents excellent value in discriminating sepsis patients and exhibits positive association with general disease severity, organ injury, inflammation level, and mortality in sepsis patients. J Clin Lab Anal. 2020;34(6):e23222.PubMedPubMedCentralCrossRef

42.

Huang X, Zhao M. High expression of long non-coding RNA MALAT1 correlates with raised acute respiratory distress syndrome risk, disease severity, and increased mortality in sepstic patients. Int J Clin Exp Pathol. 2019;12(5):1877–87.PubMedPubMedCentral

43.

Na L, Ding H, Xing E, Gao J, Liu B, Wang H, Yu J, Yu C. Lnc-MEG3 acts as a potential biomarker for predicting increased disease risk, systemic inflammation, disease severity, and poor prognosis of sepsis via interacting with miR-21. J Clin Lab Anal. 2020;34(4):e23123.PubMedPubMedCentralCrossRef

44.

Zhao D, Li S, Cui J, Wang L, Ma X, Li Y. Plasma miR-125a and miR-125b in sepsis: correlation with disease risk, inflammation, severity, and prognosis. J Clin Lab Anal. 2020;34(2):e23036.PubMedPubMedCentralCrossRef

45.

Mahmoodpoor A, Movassaghpour A, Talebi M, Shadvar K, Soleimanpour H. Value of flow cytometry (HLA-DR, CD14, CD25, CD13, CD64) in prediction of prognosis in critically ill septic patients admitted to ICU: a pilot study. J Clin Anesth. 2020;61:109646.PubMedCrossRef

46.

Yin WP, Li JB, Zheng XF, An L, Shao H, Li CS. Effect of neutrophil CD64 for diagnosing sepsis in emergency department. World J Emerg Med. 2020;11(2):79–86.PubMedPubMedCentralCrossRef

47.

Kondo Y, Umemura Y, Hayashida K, Hara Y, Aihara M, Yamakawa K. Diagnostic value of procalcitonin and presepsin for sepsis in critically ill adult patients: a systematic review and meta-analysis. J Intensive Care. 2019;7:22.PubMedPubMedCentralCrossRef

48.

Lu B, Zhang Y, Li C, Liu C, Yao Y, Su M, Shou S. The utility of presepsin in diagnosis and risk stratification for the emergency patients with sepsis. Am J Emerg Med. 2018;36(8):1341–5.PubMedCrossRef

49.

Şen S, Kamit F, İşgüder R, Yazıcı P, Bal Z, Devrim İ, Bayram SN, Karapınar B, Anıl AB, Vardar F. Surface TREM-1 as a Prognostic Biomarker in Pediatric Sepsis. Indian J Pediatr. 2020;88:134–40.PubMedCrossRef

50.

Andrés C, Andaluz-Ojeda D, Cicuendez R, Nogales L, Martín S, Martin-Fernandez M, Almansa R, Calvo D, Esteban-Velasco MC, Vaquero-Roncero LM, et al. MR- proADM to detect specific types of organ failure in infection. Eur J Clin Invest. 2020;50(6):19.CrossRef

51.

Schuetz P, Hausfater P, Amin D, Amin A, Haubitz S, Faessler L, Kutz A, Conca A, Reutlinger B, Canavaggio P, et al. Biomarkers from distinct biological pathways improve early risk stratification in medical emergency patients: the multinational, prospective, observational TRIAGE study. Crit Care. 2015;19(377):015–1098.

52.

Elke G, Bloos F, Wilson DC, Brunkhorst FM, Briegel J, Reinhart K, Loeffler M, Kluge S, Nierhaus A, Jaschinski U, et al. The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis—a secondary analysis of a large randomised controlled trial. Crit Care (Lond, Engl). 2018;22(1):79.CrossRef

53.

Lundberg OHM, Lengquist M, Spångfors M, Annborn M, Bergmann D, Schulte J, Levin H, Melander O, Frigyesi A, Friberg H. Circulating bioactive adrenomedullin as a marker of sepsis, septic shock and critical illness. Crit Care (Lond, Engl). 2020;24(1):636.CrossRef

54.

Honore PM, Redant S, De Bels D. Reliability of biomarkers of sepsis during extracorporeal therapies: the clinician needs to know what is eliminated and what is not. Crit Care (Lond, Engl). 2020;24(1):553.CrossRef

55.

Custodero C, Wu Q, Ghita GL, Anton SD, Brakenridge SC, Brumback BA, Efron PA, Gardner AK, Leeuwenburgh C, Moldawer LL, et al. Prognostic value of NT-proBNP levels in the acute phase of sepsis on lower long-term physical function and muscle strength in sepsis survivors. Crit Care. 2019;23(1):230.PubMedPubMedCentralCrossRef

56.

Varpula M, Pulkki K, Karlsson S, Ruokonen E, Pettilä V. Predictive value of N-terminal pro-brain natriuretic peptide in severe sepsis and septic shock. Crit Care Med. 2007;35(5):1277–83.PubMedCrossRef

57.

Mihajlovic D, Brkic S, Uvelin A, Draskovic B, Vrsajkov V. Use of presepsin and procalcitonin for prediction of SeptiFast results in critically ill patients. J Crit Care. 2017;40:197–201.PubMedCrossRef

58.

Leli C, Ferranti M, Marrano U, Al Dhahab ZS, Bozza S, Cenci E, Mencacci A. Diagnostic accuracy of presepsin (sCD14-ST) and procalcitonin for prediction of bacteraemia and bacterial DNAaemia in patients with suspected sepsis. J Med Microbiol. 2016;65(8):713–9.PubMedCrossRef

59.

Klouche K, Cristol JP, Devin J, Gilles V, Kuster N, Larcher R, Amigues L, Corne P, Jonquet O, Dupuy AM. Diagnostic and prognostic value of soluble CD14 subtype (Presepsin) for sepsis and community-acquired pneumonia in ICU patients. Ann Intensive Care. 2016;6(1):59.PubMedPubMedCentralCrossRef

60.

Enguix-Armada A, Escobar-Conesa R. García-De La Torre A, De La Torre-Prados MV. Usefulness of several biomarkers in the management of septic patients: C-reactive protein, procalcitonin, presepsin and mid-regional pro-adrenomedullin. Clin Chem Lab Med. 2016;54(1):163–8.PubMedCrossRef

61.

Bloos F, Trips E, Nierhaus A, Briegel J, Heyland DK, Jaschinski U, Moerer O, Weyland A, Marx G, Gründling M, et al. Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. JAMA Intern Med. 2016;176(9):1266–76.PubMedCrossRef

62.

Bonaventura A, Carbone F, Vecchié A, Meessen J, Ferraris S, Beck E, Keim R, Minetti S, Elia E, Ferrara D, et al. The role of resistin and myeloperoxidase in severe sepsis and septic shock: results from the ALBIOS trial. Eur J Clin Investig. 2020;50:e1333.CrossRef

63.

Cao C, Gu J, Zhang J. Soluble triggering receptor expressed on myeloid cell-1 (sTREM-1): a potential biomarker for the diagnosis of infectious diseases. Front Med. 2017;11(2):169–77.PubMedCrossRef

64.

Wright SW, Lovelace-Macon L, Hantrakun V, Rudd KE, Teparrukkul P, Kosamo S, Liles WC, Limmathurotsakul D, West TE. sTREM-1 predicts mortality in hospitalized patients with infection in a tropical, middle-income country. BMC Med. 2020;18(1):159.PubMedPubMedCentralCrossRef

65.

Anderson BJ, Calfee CS, Liu KD, Reilly JP, Kangelaris KN, Shashaty MGS, Lazaar AL, Bayliffe AI, Gallop RJ, Miano TA, et al. Plasma sTNFR1 and IL8 for prognostic enrichment in sepsis trials: a prospective cohort study. Crit Care (Lond, Engl). 2019;23(1):400.CrossRef

66.

Casagranda I, Vendramin C, Callegari T, Vidali M, Calabresi A, Ferrandu G, Cervellin G, Cavazza M, Lippi G, Zanotti I, et al. Usefulness of suPAR in the risk stratification of patients with sepsis admitted to the emergency department. Intern Emerg Med. 2015;10(6):725–30.PubMedCrossRef

67.

Sharma A, Ray S, Mamidipalli R, Kakar A, Chugh P, Jain R, Ghalaut MS, Choudhury S. A comparative study of the diagnostic and prognostic utility of soluble urokinase-type plasminogen activator receptor and procalcitonin in patients with sepsis and systemic inflammation response syndrome. Indian J Crit Care Med Peer Review Off Publ Indian Soc Crit Care Med. 2020;24(4):245–51.

68.

Liu M, Zhang X, Chen H, Wang G, Zhang J, Dong P, Liu Y, An S, Wang L. Serum sPD-L1, upregulated in sepsis, may reflect disease severity and clinical outcomes in septic patients. Scand J Immunol. 2017;85(1):66–72.PubMedCrossRef

69.

Yeh CF, Wu CC, Liu SH, Chen KF. Comparison of the accuracy of neutrophil CD64, procalcitonin, and C-reactive protein for sepsis identification: a systematic review and meta-analysis. Ann Intensive Care. 2019;9(1):5.PubMedPubMedCentralCrossRef

70.

Zhang Y, Feng Q, Zhou S, Chen H. Downregulation of serum survivin correlates with increased inflammation, enhanced disease severity and worse prognosis in sepsis patients. Medicine. 2020;99(28):0000000000020272.CrossRef

71.

Hoppensteadt D, Tsuruta K, Hirman J, Kaul I, Osawa Y, Fareed J. Dysregulation of inflammatory and hemostatic markers in sepsis and suspected disseminated intravascular coagulation. Clin Appl Thromb Hemost. 2015;21(2):120–7.PubMedCrossRef

72.

Hamed S, Behnes M, Pauly D, Lepiorz D, Barre M, Becher T, Lang S, Akin I, Borggrefe M, Bertsch T, et al. Diagnostic value of Pentraxin-3 in patients with sepsis and septic shock in accordance with latest sepsis-3 definitions. BMC Infect Dis. 2017;17(1):554.PubMedPubMedCentralCrossRef

73.

Tian R, Wang X, Pan T, Li R, Wang J, Liu Z, Chen E, Mao E, Tan R, Chen Y, et al. Plasma PTX3, MCP1 and Ang2 are early biomarkers to evaluate the severity of sepsis and septic shock. Scand J Immunol. 2019;90(6):7.CrossRef

74.

Barre M, Behnes M, Hamed S, Pauly D, Lepiorz D, Lang S, Akin I, Borggrefe M, Bertsch T, Hoffmann U. Revisiting the prognostic value of monocyte chemotactic protein 1 and interleukin-6 in the sepsis-3 era. J Crit Care. 2018;43:21–8.PubMedCrossRef

75.

Karlsson S, Pettilä V, Tenhunen J, Laru-Sompa R, Hynninen M, Ruokonen E. HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis. Intensive Care Med. 2008;34(6):1046–53.PubMedCrossRef

76.

Karakike E, Adami ME, Lada M, Gkavogianni T, Koutelidakis IM, Bauer M, Giamarellos-Bourboulis EJ, Tsangaris I. Late peaks of hmgb1 and sepsis outcome: evidence for synergy with chronic inflammatory disorders. Shock. 2019;52(3):334–9.PubMedCrossRef

77.

Lerman YV, Lim K, Hyun YM, Falkner KL, Yang H, Pietropaoli AP, Sonnenberg A, Sarangi PP, Kim M. Sepsis lethality via exacerbated tissue infiltration and TLR-induced cytokine production by neutrophils is integrin α3β1-dependent. Blood. 2014;124(24):3515–23.PubMedPubMedCentralCrossRef

78.

Sarangi PP, Hyun YM, Lerman YV, Pietropaoli AP, Kim M. Role of β1 integrin in tissue homing of neutrophils during sepsis. Shock (Augusta, Ga). 2012;38(3):281–7.CrossRef

79.

Fang Y, Li C, Shao R, Yu H, Zhang Q. The role of biomarkers of endothelial activation in predicting morbidity and mortality in patients with severe sepsis and septic shock in intensive care: a prospective observational study. Thromb Res. 2018;171:149–54.PubMedCrossRef

80.

Yao B, Zhang LN, Ai YH, Liu ZY, Huang L. Serum S100β is a better biomarker than neuron-specific enolase for sepsis-associated encephalopathy and determining its prognosis: a prospective and observational study. Neurochem Res. 2014;39(7):1263–9.PubMedCrossRef

81.

Mikacenic C, Hahn WO, Price BL, Harju-Baker S, Katz R, Kain KC, Himmelfarb J, Liles WC, Wurfel MM. Biomarkers of endothelial activation are associated with poor outcome in critical illness. PLoS ONE. 2015;10(10):e0141251.PubMedPubMedCentralCrossRef

82.

Crenn P, Neveux N, Chevret S, Jaffray P, Cynober L, Melchior JC, Annane D. Plasma L-citrulline concentrations and its relationship with inflammation at the onset of septic shock: a pilot study. J Crit Care. 2014;29(2):315.e311-316.CrossRef

83.

Ware LB, Magarik JA, Wickersham N, Cunningham G, Rice TW, Christman BW, Wheeler AP, Bernard GR, Summar ML. Low plasma citrulline levels are associated with acute respiratory distress syndrome in patients with severe sepsis. Crit Care. 2013;17(1):1–8.CrossRef

84.

Zhu X. MiR-125b but not miR-125a is upregulated and exhibits a trend to correlate with enhanced disease severity, inflammation, and increased mortality in sepsis patients. J Clin Lab Anal. 2020;34(3):e23094.PubMedCrossRef

85.

Gui F, Peng H, Liu Y. Elevated circulating lnc-ANRIL/miR-125a axis level predicts higher risk, more severe disease condition, and worse prognosis of sepsis. J Clin Lab Anal. 2019;33(6):e22917.PubMedPubMedCentralCrossRef

86.

Westhoff D, Engelen-Lee JY, Hoogland ICM, Aronica EMA, van Westerloo DJ, van de Beek D, van Gool WA. Systemic infection and microglia activation: a prospective postmortem study in sepsis patients. Immun Ageing. 2019;16(18):019–0158.

87.

Ehler J, Petzold A, Wittstock M, Kolbaske S, Gloger M, Henschel J, Heslegrave A, Zetterberg H, Lunn MP, Rommer PS, et al. The prognostic value of neurofilament levels in patients with sepsis-associated encephalopathy—a prospective, pilot observational study. PLoS ONE. 2019;14(1):e0211184.PubMedPubMedCentralCrossRef

88.

Anderson BJ, Reilly JP, Shashaty MGS, Palakshappa JA, Wysoczanski A, Dunn TG, Kazi A, Tommasini A, Mikkelsen ME, Schweickert WD, et al. Admission plasma levels of the neuronal injury marker neuron-specific enolase are associated with mortality and delirium in sepsis. J Crit Care. 2016;36:18–23.PubMedPubMedCentralCrossRef

89.

90.

Aksaray S, Alagoz P, Inan A, Cevan S, Ozgultekin A. Diagnostic value of sTREM-1 and procalcitonin levels in the early diagnosis of sepsis. North Clin Istanb. 2016;3(3):175–82.PubMed

91.

Brenner T, Uhle F, Fleming T, Wieland M, Schmoch T, Schmitt F, Schmidt K, Zivkovic AR, Bruckner T, Weigand MA, et al. Soluble TREM-1 as a diagnostic and prognostic biomarker in patients with septic shock: an observational clinical study. Biomark Biochem Ind Expos Response Susceptibility Chem. 2017;22(1):63–9.

92.

Spoto S, Cella E, de Cesaris M, Locorriere L, Mazzaroppi S, Nobile E, Lanotte AM, Pedicino L, Fogolari M, Costantino S, et al. Procalcitonin and MR-proadrenomedullin combination with SOFA and qSOFA Scores for Sepsis diagnosis and prognosis: a diagnostic algorithm. Shock (Augusta, Ga). 2018;50(1):44–52.CrossRef

93.

Yang Y, Liang S, Geng J, Wang Q, Wang P, Cao Y, Li R, Gao G, Li L. Development of a nomogram to predict 30-day mortality of patients with sepsis-associated encephalopathy: a retrospective cohort study. J Intensive Care. 2020;8(45):020–00459.

94.

Bonaventura A, Carbone F, Vecchié A, Meessen J, Ferraris S, Beck E, Keim R, Minetti S, Elia E, Ferrara D, et al. The role of resistin and myeloperoxidase in severe sepsis and septic shock: Results from the ALBIOS trial. Eur J Clin Invest. 2020;50(10):13.CrossRef

95.

Maruchi Y, Tsuda M, Mori H, Takenaka N, Gocho T, Huq MA, Takeyama N. Plasma myeloperoxidase-conjugated DNA level predicts outcomes and organ dysfunction in patients with septic shock. Crit Care. 2018;22(1):018–2109.CrossRef

96.

Karampela I, Christodoulatos GS, Kandri E, Antonakos G, Vogiatzakis E, Dimopoulos G, Armaganidis A, Dalamaga M. Circulating eNampt and resistin as a proinflammatory duet predicting independently mortality in critically ill patients with sepsis: a prospective observational study. Cytokine. 2019;119:62–70.PubMedCrossRef

97.

Saboktakin L, Bilan N, Ghalehgolab Behbahan A, Poorebrahim S. Relationship between resistin levels and sepsis among children under 12 years of age: a case control study. Front Pediatr. 2019;7:355.PubMedPubMedCentralCrossRef

98.

Ritter C, Tomasi CD, Dal-Pizzol F, Pinto BB, Dyson A, de Miranda AS, Comim CM, Soares M, Teixeira AL, Quevedo J, et al. Inflammation biomarkers and delirium in critically ill patients. Crit Care. 2014;18(3):1–6.CrossRef

99.

Feng Q, Wei WQ, Chaugai S, Leon BGC, Mosley JD, Leon DAC, Jiang L, Ihegword A, Shaffer CM, Linton MF, et al. Association between low-density lipoprotein cholesterol levels and risk for sepsis among patients admitted to the hospital with infection. JAMA Netw Open. 2019;2(1):e187223.PubMedPubMedCentralCrossRef

100.

Chien JY, Jerng JS, Yu CJ, Yang PC. Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit Care Med. 2005;33(8):1688–93.PubMedCrossRef

101.

Cirstea M, Walley KR, Russell JA, Brunham LR, Genga KR, Boyd JH. Decreased high-density lipoprotein cholesterol level is an early prognostic marker for organ dysfunction and death in patients with suspected sepsis. J Crit Care. 2017;38:289–94.PubMedCrossRef

102.

Takegawa R, Kabata D, Shimizu K, Hisano S, Ogura H, Shintani A, Shimazu T. Serum albumin as a risk factor for death in patients with prolonged sepsis: an observational study. J Crit Care. 2019;51:139–44.PubMedCrossRef

103.

Sui YD, Xin WN, Feng LL. Comparison of the clinical application values of PCT, hs-CRP and SAA detection in the early diagnosis of sepsis. Pak J Med Sci. 2020;36(7):1683–7.PubMedPubMedCentralCrossRef

104.

Hou X, Liu C, Lian H, Xu Z, Ma L, Zang X, Sun J, Jia K, Cui L. The value of neutrophil gelatinase-associated lipocalin and citrullinated alpha enolase peptide-1 antibody in diagnosis, classification, and prognosis for patients with sepsis. Medicine. 2020;99(34):0000000000021893.CrossRef

105.

Zhang H, Wang X, Zhang Q, Xia Y, Liu D. Comparison of procalcitonin and high-sensitivity C-reactive protein for the diagnosis of sepsis and septic shock in the oldest old patients. BMC Geriatr. 2017;17(1):017–0566.CrossRef

106.

Lin R, Hu H, Li L, Chen G, Luo L, Rao P. The potential of microRNA-126 in predicting disease risk, mortality of sepsis, and its correlation with inflammation and sepsis severity. J Clin Lab Anal. 2020;34(9):2.CrossRef

107.

Zeng Q, Wu J, Yang S. Circulating lncRNA ITSN1-2 is upregulated, and its high expression correlates with increased disease severity, elevated inflammation, and poor survival in sepsis patients. J Clin Lab Anal. 2019;33(4):25.CrossRef

108.

Piazza O, Russo E, Cotena S, Esposito G, Tufano R. Elevated S100B levels do not correlate with the severity of encephalopathy during sepsis. Br J Anaesth. 2007;99(4):518–21.PubMedCrossRef

109.

110.

Chen J, He Y, Zhou L, Deng Y, Si L. Long non-coding RNA MALAT1 serves as an independent predictive biomarker for the diagnosis, severity and prognosis of patients with sepsis. Mol Med Rep. 2020;21(3):1365–73.PubMed

111.

Zhao D, Li S, Cui J, Wang L, Ma X, Li Y. Plasma miR-125a and miR-125b in sepsis: correlation with disease risk, inflammation, severity, and prognosis. J Clin Lab Anal. 2020;34(2):23036.CrossRef

112.

Ehler J, Saller T, Wittstock M, Rommer PS, Chappell D, Zwissler B, Grossmann A, Richter G, Reuter DA, Nöldge-Schomburg G, et al. Diagnostic value of NT-proCNP compared to NSE and S100B in cerebrospinal fluid and plasma of patients with sepsis-associated encephalopathy. Neurosci Lett. 2019;692:167–73.PubMedCrossRef

113.

Aksaray S, Alagoz P, Inan A, Cevan S, Ozgultekin A. Diagnostic value of sTREM-1 and procalcitonin levels in the early diagnosis of sepsis. North Clin Istanb. 2017;3(3):175–82.PubMedPubMedCentral

114.

Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet (Lond, Engl). 1993;341(8844):515–8.CrossRef

115.

Titel: Biomarkers for sepsis: more than just fever and leukocytosis—a narrative review
verfasst von: Tatiana Barichello
Jaqueline S. Generoso
Mervyn Singer
Felipe Dal-Pizzol
Publikationsdatum: 01.12.2022
Verlag: BioMed Central
Erschienen in: Critical Care / Ausgabe 1/2022
Elektronische ISSN: 1364-8535
DOI: https://doi.org/10.1186/s13054-021-03862-5

Neu im Fachgebiet AINS

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Delir bei kritisch Kranken – Antipsychotika versus Placebo

16.05.2024 Delir Nachrichten

Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Biomarkers for sepsis: more than just fever and leukocytosis—a narrative review

Abstract

Publisher's Note

Introduction

The humoral innate immune response, cytokines, and chemokines

DAMPs

Endothelial cells and BBB markers

Gut permeability markers

Non-coding RNAs and miRNA

Membrane receptors, cell proteins, and metabolites

Hormones and peptide precursors

Soluble receptors

Conclusion

Acknowledgements

Declarations

Competing interests

Publisher's Note

Neu im Fachgebiet AINS

Mehr Frauen im OP – weniger postoperative Komplikationen

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Delir bei kritisch Kranken – Antipsychotika versus Placebo

Klinikreform soll zehntausende Menschenleben retten

Update AINS

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Publisher's Note

Introduction

The humoral innate immune response, cytokines, and chemokines

DAMPs

Endothelial cells and BBB markers

Gut permeability markers

Non-coding RNAs and miRNA

Membrane receptors, cell proteins, and metabolites

Hormones and peptide precursors

Neutrophil-related biomarkers

Soluble receptors

Conclusion

Acknowledgements

Declarations

Ethics approval and consent to participate

Consent for publication

Competing interests

Publisher's Note

Weitere Artikel der Ausgabe 1/2022

Hyperoxemia in postsurgical sepsis/septic shock patients is associated with reduced mortality

Time-varying intensity of oxygen exposure is associated with mortality in critically ill patients with mechanical ventilation

Ischemic injury of the upper gastrointestinal tract after out-of-hospital cardiac arrest: a prospective, multicenter study

Higher serum haptoglobin levels were associated with improved outcomes of patients with septic shock

Wearable ultrasound and provocative hemodynamics: a view of the future

Early prolonged prone position in noninvasively ventilated patients with SARS-CoV-2-related moderate-to-severe hypoxemic respiratory failure: clinical outcomes and mechanisms for treatment response in the PRO-NIV study

Neu im Fachgebiet AINS

Mehr Frauen im OP – weniger postoperative Komplikationen

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Delir bei kritisch Kranken – Antipsychotika versus Placebo

Klinikreform soll zehntausende Menschenleben retten

Update AINS